1. TITLE PAGE 
 
CLINICAL STUDY PROTOCOL 
 
Amendment No. 2 Final Version Date:  31 July 2018 
Amendment No. 1 Final  Version Date:  19 October 2017 
Original Final Version Date:   26 July 2017 
 
A Phase 2b, Randomized, Double- Blind, Placebo -Controlled, Dose 
Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI -
98854 for the Treatment of Pe diatric Subjects with Tourette Syndrome  
 
Study No.:  NBI-98854-TS2003 
 
Development Phase:  Phase 2b 
 
Sponsor: Neurocrine Biosciences, Inc.  
 12780 El Camino Real 
 San Diego, CA 92130 
 Telephone:  ( 858) 617-7600 
 Facsimile:   (858) 617-7705 
 
 
CONFIDENTIAL  
This document is a confidential communication of Neurocrine Biosciences, Inc.  It is agreed that 
no unpublished information contained herein will be published or disclosed without prior 
approval from the Sponsor.  However, this document can be disclosed to an appropriate 
Institutional Review Board/Ethics Committee (IRB/EC) or authorized representatives of national 
regulatory authorities under the condition that they respect its confidential nature.  
SIGNATURES:  
I agree to conduct this study in accordance with the requirements of this clinical study protocol 
and also in accordance with the following: 
• Established principles of Good Clinical Practice (GCP) (Harmoni sed) 
• United States (US) Code of Federal Regulations (CFR); US Food and Drug Administration 
(FDA) ; Health Canada. 
 
CLINICAL STUDY TITLE : 
A Phase 2b, Randomized, Double- Blind, Placebo -Controlled, Dose Optimization Study to 
Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric 
Subjects with Tourette Syndrome  PROTOCOL No.:  NBI-98854- TS2003 
 As Agreed:  
 ____________________________________ _______________________ Principal  Investigator  Signature Date  
 PRINCIPAL INVESTIGATOR:  
 ______________________________________________________________ (Print Principal Investigator Name)  
 SITE:    ________________________________________________________ (Print Site Name)  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 2
Neurocrine Biosciences , Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version 
Accepted for the Sponsor: 
SPONSOR: 
Jj3\ 
Date 
31July2018 Neurocrine Biosciences, Inc. 
12780 El Camino Real 
San Diego, CA 92130 
Phone : (858) 617- 7600 
Facsimile: (858) 617- 7705 
Confidential Page 3 
LIST OF SPONSOR PERSONNEL  
Neurocrine Biosciences, Inc.  
12780 El Camino Real 
San Diego, CA 92130 
Medical Monitor:  
Telephone:  
Facsimile:  
Cell Phone: 
Vice President, Clinical Development:  
Telephone:  
Facsimile:   
Serious Adverse Event Report ng:
Telephone:  
Facsimile:   
Email:    
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 4
TABLE OF CONTENTS  
1. TITLE PAGE  ................................................................................................. 1  
2. SYNOPSIS  .................................................................................................. 10  
3. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS .............. 14  
4. ETHICS  ....................................................................................................... 16  
5. INTRODUCTION  ....................................................................................... 16  
5.1. Background .................................................................................................. 16  
5.2. NBI-98854 ................................................................................................... 17  
5.3. Study and Dose Rationale  ............................................................................ 19  
6. STUDY OBJECTIVES  ............................................................................... 20  
7. OVERVIEW OF STUDY DESIGN  ............................................................ 20  
8. STUDY POPULATION  .............................................................................. 24  
8.1. Inclusion Criteria ......................................................................................... 24  
8.2. Exclusion Criteria ........................................................................................ 25  
8.3. Subject Identification and Replacement  ...................................................... 27  
8.4. Randomization  ............................................................................................. 27  
9. STUDY EVALUATIONS  ........................................................................... 27  
9.1. Schedule of Assessments  ............................................................................. 27  
9.2. Screening and Baseline Assessments  .......................................................... 30  
9.2.1.  Genotyping .................................................................................................. 30  
9.3. Effic acy Assessments  .................................................................................. 30  
9.3.1.  Yale Global Tic Severity Scale  .................................................................... 30  
9.3.2.  Premonitory Urge for Tics Scale  ................................................................. 30  
9.3.3.  Clinical Global Impression Scales  ............................................................... 31  
9.3.4.  Gilles de la Tourette Syndrome-Quality of Life for Children and 
Adolescents  .................................................................................................. 31  
9.4. Pharmacokinetic Evaluations  ....................................................................... 31  
9.5. Safety Assessments  ...................................................................................... 32  
9.5.1.  Data Safety Monitoring Board ..................................................................... 32 
9.5.2.  Vital Sign Measurements  ............................................................................. 32  
9.5.3.  Medical History  ........................................................................................... 32  
9.5.4.  Physical Examination, Including Height and Weight .................................. 33  
9.5.5.  Electrocardiogram  ........................................................................................ 33  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 5
9.5.6.  Clinical Laboratory Assessments  ................................................................ 33  
9.5.7.  Columbia- Suicide Severity Rating Scale Children’s Versions  ................... 34  
9.5.8.  Children’s Depression Rating Scale- Revised  .............................................. 35  
9.5.9.  Children’s Yale- Brown Obsessive Compulsive Scale  ................................ 35  
9.5.10.  Attention -Deficit Hyperactivity Disorder  Rating Scale- 5:  Home Version  . 35 
9.5.11.  Extrapyramidal Symptom Rating Scale-Abbreviated  ................................. 35  
9.5.12.  Estimated Total Blood Sample Volume Required by Study  ....................... 35  
9.6. Specific Study Information  .......................................................................... 36  
9.6.1.  Screening (Days -28 to -1) ........................................................................... 36  
9.6.2.  Day 1 (Baseline Assessments and Start of Dosing)  ..................................... 37  
9.6.3.  Dose Optimization Period:  Weeks 2, 4, and 6 (-2 to +3 Days for Each 
Visit)  ............................................................................................................ 38  
9.6.4.  Dose Maintenance Period:  Weeks 8, 10, and 12 (-2 to +3 Days for Each Visit)  ............................................................................................................ 40
 
9.6.5.  Follow-Up Period/Early Termination:  Week 14 (-2 to +3 Days) ............... 41  
9.7. Study Duration ............................................................................................. 41  
9.8. Prohibitions and Restrictions ....................................................................... 42  
9.8.1.  Prior and Concomitant Medications ............................................................ 42  
9.8.2.  Dietary Restrictions  ..................................................................................... 42  
9.8.3.  Other Restrictions  ........................................................................................ 42  
9.9. Withdrawal Criteria  ..................................................................................... 43  
9.9.1.  Handling of Withdrawals ............................................................................. 43  
9.9.2.  Sponsor’s Termination of Study .................................................................. 43  
10. STUDY DRUG ............................................................................................ 44  
10.1.  Study Dr ug Supplies  .................................................................................... 44  
10.2.  Study Drug Storage...................................................................................... 44  
10.3.  Study Drug Packaging and Labeling  ........................................................... 45  
10.4.  Blinding ....................................................................................................... 45  
10.5.  Study Drug Administration .......................................................................... 45 
10.6.  Drug Compliance and Accountability  ......................................................... 45  
10.7.  Study Drug Return ....................................................................................... 46  
11. ADVERSE EVENTS ................................................................................... 46 
11.1.  Definition  ..................................................................................................... 46  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 6
11.2.  Intensity of Adverse Events  ......................................................................... 47  
11.3.  Relationship to Study Drug ......................................................................... 47  
11.4.  Recording Adverse Events .......................................................................... 48  
11.5.  Post-Study Follow -Up of Adverse Events ................................................... 48  
11.6.  Serious Adverse Events  ............................................................................... 49  
11.6.1.  Definition of a Serious Adverse Event  ........................................................ 49  
11.6.2.  Managing Serious Adverse Events  .............................................................. 49  
11.6.3.  Reporting Serious Adverse Events and Other Immediately Reportable 
Events  .......................................................................................................... 50  
11.6.4.  Expedited Safety Reports ............................................................................ 50  
11.7.  Pregnancy .................................................................................................... 50  
12. DOCUMENTATION OF DAT A ................................................................ 51  
12.1.  Case Report Form ........................................................................................ 51  
12.2.  Data Capture, Review, and Validation  ........................................................ 51  
12.3.  Coding Dictionaries  ..................................................................................... 52  
13. STATISTICAL AND ANAL YTICAL PLAN  ............................................ 52  
13.1.  Analysis Sets  ................................................................................................ 53  
13.2.  Sample Size  ................................................................................................. 53  
13.3.  Hand ling of Missing Data ............................................................................ 53  
13.4.  Enrollment and Disposition of Subjects ...................................................... 54  
13.5.  Demographics and Baseline Characteristics  ................................................ 54  
13.6.  Study Drug Dosing and Compliance ........................................................... 54  
13.7.  Pharmacokinetic Data  .................................................................................. 54  
13.8.  Efficacy Data  ............................................................................................... 54  
13.8.1.  Primary Efficacy Endpoint  .......................................................................... 54  
13.8.2.  Secondary Efficacy Endpoints ..................................................................... 55  
13.8.3.  Procedure to Control for Multiple Comparisons ......................................... 56  
13.8.4.  Exploratory Efficacy Endpoints .................................................................. 57  
13.9.  Safety Data................................................................................................... 57 
13.10.  Software ....................................................................................................... 57  
13.11.  Interim Analysis ........................................................................................... 57 
14. REGULATORY AND ETHIC AL ISSUES ................................................ 57  
14.1.  General Legal References  ............................................................................ 57  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 7
14.2.  Institutional Review Board  .......................................................................... 58  
14.3.  Protocol Adhere nce and Amendments  ........................................................ 58  
14.4.  Required Documents ................................................................................... 58  
14.5.  Informed Consent ........................................................................................ 58  
14.6.  Study Monitoring ......................................................................................... 59  
14.7.  Quality Assurance ........................................................................................ 59  
14.8.  Record Retention ......................................................................................... 59  
14.9.  Confidentiality ............................................................................................. 59  
15. STUDY COMMENCEMENT A ND DISCONTINUATION ..................... 60  
16. REFERENCES ............................................................................................ 61  
17. APPENDICES  ............................................................................................. 63  
17.1.  Yale Global Tic Severity Scale (YGTSS)  ................................................... 63  
17.2.  Premonitory Urge for Tics Scale (PUTS)  .................................................... 68  
17.3.  Clinical Global Impression of Tics (CGI -Tics) – Severity  .......................... 70  
17.4.  Clinical Global Impression of Tourette Syndrome (CGI- TS) – Improvement 
scale  ............................................................................................................. 72  
17.5.  Gilles de la Tourette Syndrom e-Quality of Life for Children and 
Adolescents  .................................................................................................. 74  
17.6.  Columbia- Suicide Severity Rating Scale (C -SSRS) Children’s 
Baseline/Screening Version ......................................................................... 80  
17.7.  Columbia- Suicide Severity Rating Scale (C -SSRS) Children’s Since Last 
Visit Version  ................................................................................................ 84  
17.8.  Children’s Depression Rating Scale, Revised (CDRS-R) ........................... 88  
17.9.  Children’s Yale-Brown Obs essive Compulsive Scale (CY -BOCS)  ........... 93  
17.10.  Attention -Deficit Hyperactivity Disorder Rating Scale- 5: Home Version  117  
17.11.  Extrapyramidal Symptom Rating Scale-Abbreviated  ............................... 122  
 
LIST OF TABLES  
Table 1:  Treatment by Weight Group  ........................................................................ 20  
Table 2:  Schedule of Assessments  ............................................................................. 28  
Table 3:  Estimated Total Blood Sample Volume  ...................................................... 36  
Table 4:  Intensity of Adverse Events  ......................................................................... 47  
Table 5: Relationship of Adverse Events to Study Drug ........................................... 48  
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 8
LIST OF FIGURES  
Figure 1:  Study Design Schematic  .............................................................................. 23  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 9
2. SYNOPSIS 
Protocol Title:  
A Phase 2b, Randomized, Double -Blind, Placebo -Controlled, Dose Optimization Study to Assess the 
Safety, Tolerability, and Efficacy of NBI -98854 for the Treatment of Pediatric Subjects with Tourette 
Syndrome  
Study Centers:   Approximately 55 study centers in North America . 
Objectives:  
Primary:  
• To evaluate the efficacy of NBI -98854, titrated to the subject's optimal dose in the range of 20 mg to 
60 mg for subjects <50 kg and 40 mg to 80 mg for subjects ≥50 kg, administered once daily (qd) for 
the treatment of Tourette syndrome (TS).  
Secondary:  
• To evaluate the safety and tolerability of NBI -98854, titrated to the subject's optimal dose in the 
range of 20 mg to 60 mg for subjects <50 kg and 40 mg to 80 mg for subjects ≥50 kg, administered 
once daily.  
• To evaluate plasma exposure measures of NBI- 98854 and its active metabolite, NBI -98782, 
following titrated doses of NBI -98854 from 20 mg to 60 mg for subjects <50 kg and 40 mg to 80  mg 
for subjects ≥50 kg.  
Methodology:  This is a Phase 2b, randomized, double -blind, placebo- controlled, dose -optimization 
study to evaluate the efficacy, safety, and tolerability of NBI -98854 titrated to the subject’s optimal dose 
in the range of 20 mg to 60 mg for subjects <50 kg and 40 mg to  80 mg for subjects ≥50 kg compared to 
placebo, administered qd for a total of 12 weeks of treatment in pediatric subjects with TS.  
Approximately 120 male and female pediatric subjects, 6 to 17 years of age, with a Diagnostic and 
Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM -IV or -V) diagnosis of TS will 
participate.  There will be an approximately equal distribution of subjects in each weight group, <50 kg 
and ≥50 kg, enrolled into the study and subjects will be stratified based on the ir weight.  Eligible 
subjects will be randomized in a 1:1 ratio to NBI -98854 or placebo treatment as depicted in the 
following table:  
Weight Group  
 Assigned Treatment  Number of Subjects  
(approximate) 
Subjects <50 kg at baseline  
 Placebo  30 
 NBI-98854 (20 to 60 mg)  30 
Subjects ≥50 kg at baseline  
 Placebo  30 
 NBI-98854 (40 to 80 mg)  30 
For subjects randomized to active treatment, the starting dose will be NBI -98854 20 mg for subjects 
<50 kg at baseline and NBI -98854 40 mg for subjects ≥50 kg at baseline, which may be escalated in 
increments of 20 mg every 2 weeks to a maximum of 60 mg fo r subjects <50 kg and 80 mg for subjects 
≥50 kg to achieve an optimal dose of NBI -98854 for each subject.  To maintain the study blind, subjects 
randomized to placebo in each weight group will be subjected to the same dose escalation requirements but will receive only placebo during the treatment period.   
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 10
Dose escalations will occur at the end of Weeks 2 and 4 based on the following 2 criteria:  1) the 
subject ’s tics are not sufficiently controlled per physician investigator assessment; and 2) an evaluation 
by the physician investigator indicates that the subject is tolerating the study drug at the current dose and 
would likely be able to tolerate the next dose level.  During the first 6  weeks of the 12 -week double -
blind treatment period, the physician inv estigator may escalate a subject’s dose to the next dose level, 
continue with the subject’s current dose, or reduce to the subject’s prior tolerated dose (in subjects who have had a dose escalation).  After Week 6, subjects will continue to receive their optimized dose of NBI-98854 or placebo for an additional 6- week dose maintenance period.  If a subject’s optimal dose 
has already been established at Week 2 (or at Week 4 ), no further dose escalation will be allowed during 
the dose optimization period and t he subject will continue at that dose until the end of the 12 -week 
treatment period.  At any time after Week 2, the physician investigator may decrease the dose to the 
previous dose for any subject who had a dose escalation and who is unable to tolerate a given dose 
increase.  The subject will continue at that dose until the end of the 12 -week treatment period.  The 
investigator may reduce the subject’s dose only one time.  Subjects who are unable to tolerate the starting dose or resumption of the previous dose will be discontinued from the study.  Follow -up 
assessments will be conducted at the end of Week 14 (2 weeks after the last dose of the study drug).  
After providing parental or legal guardian informed consent with signed and witnessed pediatric assent , 
subjects will be screened to determine eligibility within 28 days (Days -28 to -1) before the start of study 
drug dosing on Day 1.  On Day 1 (baseline), eligible subjects will return to the study center for collection of baseline safety and efficacy assessments, and the collection of a blood sample for subsequent determination of their cytochrome P450 2D6 (CYP2D6) metabolizer status.  Subjects who 
continue to be eligible for the study will then be randomized (1:1) to placebo or NBI -98854, with 
assigned dose based on weight group at baseline.  A 2 -week supply of study drug will be dispensed.  
Beginning on Day 1, study drug will be administered qd at home at the subject’s bedtime under the 
supervision of the subject’s parent/legal guardian.  Subjects will con tinue to self -administer the study 
drug daily at approximately the same time for the duration of the 12 -week treatment period.  Subjects 
will return to the study center at fixed intervals (end of Weeks 2, 4, 6, 8, 10, and 12) for study 
assessments and disp ensing of study drug (Weeks 2, 4, 6, 8, and 10 only).  As much as possible, these 
study visits and the follow -up visit should occur at the same time as the Day 1 (baseline) visit to 
standardize the time of day for the assessment of efficacy, safety, and plasma exposure.  A representative from the study center will call the subject or parent/legal guardian 3 to 7 days after the start of dosing to inquire about any study drug -related issues with respect to compliance or tolerability.  
All subjects who complete the 12 -week treatment period will enter a 2 -week follow -up period with a 
follow -up visit at Week 14 (subjects who terminate early will have Week 14 assessments conducted).  
Efficacy, safety, and study drug exposure will be assessed at scheduled times t hroughout the study.  The 
treatment period visits (Weeks 2, 4, 6, 8, 10, and 12) and the follow -up visit (Week 14) will have a visit 
window of -2 or +3 days.  An independent Data Safety Monitoring Board (DSMB) will periodically 
review ongoing clinical safety data to ensure the safety and well-being of the study subjects.  
Efficacy assessments for TS are the Yale Global Tic Severity Scale (YGTSS; primary), Clinical Global 
Impression of Tourette Syndrome -Improvement scale (CGI -TS-Improvement), Clinical Global 
Impression of Tics-Severity scale (CGI -Tics-Severity), the Premonitory Urge for Tics Scale (PUTS), 
and the Gilles de la Tourette Syndrome – Quality of Life Scale for Children and Adolescents 
(C&A -GTS -QOL).  The YGTSS, PUTS, and C&A -GTS -QOL will be administered at screening, on 
Day 1 (baseline), and at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit or at early termination).  At 
screening and Day 1 (baseline), the CGI- Tics-Severity scale will be used, and then both the 
CGI-TS-Improvement and CGI -Tics-Severity will be used to rate the overall severity and improvement 
of tics at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit or at early termination).  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 11
The YGTSS will serve as the primary assessment of tic behaviors associated with TS.  The YGTSS is 
designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions:  number, frequency, intensity, complexity, and interference.  The scale also includes an impairment assessment.  The YGTSS will be administered by a trained and certified rater (eg, the investigator or quali fied designee) using a computer- based structured clinical interview.  At each timepoint, the YGTSS 
interview will be video recorded in its entirety.  The video -recording will follow a standardized set of 
guidelines and the recorded video will be uploaded to a se cure central server.  An  external video 
reviewer, not affiliated with the site, will access the central server to view the recording and 1) confirm the subject’s TS severity is at least moderate based on a CGI -Tics-Severity of ≥4 (at screening only), and 
2) determine if the YGTSS interview program was administered properly.  The computer software system for the YGTSS administration, Rater Station™ (Bracket Global, LLC; Philadelphia, PA), will prompt the trained and certified rater to enter a score for each item of the scale based on subject and 
parent responses during the structured clinical interview.  The software will also generate individual 
scores for each item of the scale (tandem rating) and will generate the Total Tic Score (TTS) and the 
Global Tic Severity Score.  
Safety assessments including adverse event (AE) monitoring, clinical laboratory tests (hematology, clinical chemistry, and urinalysis), vital sign measurements, physical examinations,  12-lead 
electrocardiogram (ECG), Columbia -Suicide Severity Rating Scale (C -SSRS, Children’s Version), 
Children’s Depression Rating Scale - Revised (CDRS -R), the Children’s Yale -Brown Obsessive 
Compulsive Scale (CY -BOCS), the Attention -Deficit Hyperactivit y Disorder Rating Scale -5:  Home 
Version (ADHD Rating Scale -5), and Extrapyramidal Symptom Rating Scale -Abbreviated (ESRS -A) 
will also be collected at scheduled times throughout the study.  
Blood samples for plasma drug and metabolite concentration analyses will be at Day 1 (baseline) and at 
Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit or at early termination).  Subjects/caregivers will be asked to record and provide dosing times from the evening before the treatment period visits when 
pharmacokinetic  (PK) samples are collected.  
Study Population:   Approximately 120 male and female pediatric subjects (6 to 17 years of age) with a 
DSM -IV or -V diagnosis of TS; approximately 60 subjects <50 kg and 60 subjects ≥50 kg will be 
enrolled into this study.  The  subjects must have at least moderate current TS symptoms, as defined by a 
CGI-Tics-Severity score of ≥4 (ie, moderately ill) at screening.  Subjects with Tourette’s spectrum 
diagnoses (eg, obsessive -compulsive disorder [OCD], attention -deficit hyperactivi ty disorder [ADHD], 
etc) must have a stable psychiatric status at screening as determined by the physician investigator.  
Duration of Treatment and Study Participation:   The expected duration of study participation for 
each subject is approximately 18 weeks, including up to 28 days of screening, a 12 -week double -blind 
treatment period, and 2 weeks of follow -up, or early termination.  
Investigational Product, Dose, and Mode of Administration:   NBI-98854 will be supplied as capsules 
containing 20 mg or 40  mg of NBI -98854 (free base equivalent).  Subjects must swallow the capsules at 
bedtime with at least 4 ounces of water with or without food .  
Reference Therapy, Dose, and Mode of Administration:  Matching placebo capsules are identical in 
appearance and will be orally administered in a double -blinded manner (2 placebo capsules) per 
randomization on an identical schedule to those receiving NBI- 98854.  S ubjects must swallow the 
capsules at bedtime with at least 4 ounces of water.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 12
Criteria for Evaluation:   
Efficacy :  The following efficacy assessments will be administered at screening, Day 1 (baseline), and 
at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit or at early termination):  
• YGTSS; TTS as the primary assessment  
• PUTS 
• C&A -GTS -QOL . 
The CGI -Tics-Severity will be used to rate the overall severity of tics beginning at screening and Day 1 
(baseline) , and then both CGI -Tics-Severity and CGI -TS-Improvement will be administered at Weeks 2, 
4, 6, 8, 10, 12, and 14 (final study visit or at ea rly termination).  
Pharmacokinetics:  Blood samples for plasma  study drug and metabolite concentration analyses will be 
collected at Day 1 (baseline)  and at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit  or early 
termination).  Subjects/caregivers will be asked to record and provide dosing times from the evening 
before the treatment period visits when PK samples are collected.  
Safety:  Safety and tolerability will be monitored throughout the study and will include the following 
assessments:  
• AEs 
• Clinical laboratory tests (hematology, clin ical chemistry, and urinalysis)  
• Serum prolactin  
• Vital signs (including orthostatic systolic and diastolic blood pressure, orthostatic pulse rate, respiratory rate, and oral body temperature)  
• Physical examinations (including height and weight)  
• 12-lead ECGs  
• C-SSRS, Children’s Version  
• CDRS -R 
• CY-BOCS  
• ADHD-5 Rating Scale  
• ESRS -A. 
Statistical Methods:   The primary efficacy endpoint is the change from baseline (Day 1) to the end of 
Week 12 in the YGTSS TTS as generated by the certified site rater using the Rater  Station™.  The 
secondary efficacy endpoint s are:  change from baseline to the end of Week 12 in CGI -Tics-Severity 
score , TTS responder status at Week 12 (a responder is defined as having a ≥30% reduction in TTS from 
baseline), and CGI -TS-Improvement responder status at Week 12 (a responder is defined as having a 
CGI-TS-Improvement score of either a 1 [“very much improved”] or 2 [“much improved”]) .  
Explorator y efficacy endpoints will include the change from baseline to the end of Week 12 for the 
PUTS total score, CGI -TS-Improvement score at the end of Week  12, change from baseline to the end of 
Week 12 for the C&A -GTS- QOL score, as well as changes from baselin e to the end of Week 12 for the 
Global Tic Severity and Impairment scores from the YGTSS.  Efficacy data will also be summarized 
from other timepoints (eg, Weeks 2 through 10).  
Statistical comparisons between NBI -98854 and placebo will be performed for th e efficacy endpoints for 
the pooled weight groups (<50 kg, ≥50 kg) and data will also be summarized for each weight group 
separately.  The analyses will include comparisons at specified timepoints.  The primary analysis of the 
YGTSS TTS change from baseline will be a mixed -effect model repeated measures (MMRM) analysis 
of the pooled weight groups including the scores at Weeks 2, 4, 6, 8, 10, and 12 based on the full 
analysis set  (FAS) .  Supplemental sensitivity analyses of the primary efficacy endpoint  will also be 
conducted.  
Safety and plasma  study drug and metabolite concentration data will be summarized for the pooled 
weight groups and each weight group separately, using descriptive statistics.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 13
3. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
ADHD  Attenti on-Deficit Hyperactivity Disorder  
ADHD Rating Scale -5 Attention -Deficit Hyperactivity Disorder Rating Scale -5:  Home Version  
AE Adverse event  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
AUC  Area under the plasma concentration versus time curve  
AUC 0-∞  AUC from 0 hours extrapolated to infinity  
β-hCG  β-human chorionic gonadotropin  
C&A -GTS -QOL  Gilles de la Tourette Syndrome – Quality of Life Scale for Children and 
Adolescents  
CBIT  Comprehensive Behavioral Intervention for Tics  
CDRS -R Children’s Depression Rating Scale - Revised  
CDS  Clinical Drug Safety  
CFR  Code of Federal Regulations  
CGI-Tics-Severity  Clinical Global Impression of Tics -Severity scale  
CGI-TS-Improvement  Clinical Global Impression of Tourette Syndrome -Improvement scale  
Cmax  Maximum plasma concentration  
CMH  Cochran -Mantel -Haenszel  
CRT  Controlled room temperature  
C-SSRS  Columbia Suicide Severity Rating Scale  
CY-BOCS  Children’s Yale -Brown Obsessive  Compulsive Scale  
CYP  Cytochrome  P450  
DSMB  Data Safety Monitoring Board  
DSM -IV or -V Diagnostic and Statistical Manual of Mental Disorders 4 th or 5th 
Editions  
EC Ethics Committee  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EDTA K 2 Dipotassium e thylenediaminetetraacetic acid  
ESRS -A Extrapyramidal Symptom Rating Scale -Abbreviated  
FAS Full analysis set  
FDA  [United States] Food and Drug Administration  
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl transferase  
HBsAg  Hepatitis B surface antigen  
HCV -Ab Hepatitis C virus antibody  
HIV-Ab Human i mmunodeficiency virus antibody  
ICF Informed c onsent form 
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
IRB Institutional Review Board  
IWRS  Interactive Web Response System  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 14
MAOI  Monoamine oxidase inhibitor  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  Mixed -effect  model repeated measures  
NBI Neurocrine Biosciences, Inc.  
PD Pharmacodynamics  
PK Pharmacokinetic(s)  
PP Per-protocol  
PUTS  Premonitory Urge for Tics Scale  
QTcF  Corrected QT interval using Fridericia’s formula  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SOC  System organ class  
t½  Terminal half life  
TD Tardive dyskinesia  
TEAE  Treatment -emergent adverse event  
tmax  Time to maximum plasma concentration  
TS Tourette syndrome  
TTS Total Tic Score  
ULN  Upper limit of normal  
US United States  
VMAT2  Vesicular monoamine transporter 2  
WBC  White blood cell  
YGTSS  Yale Global Tic Severity Scale  
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 15
4. ETHICS  
The study will be conducted in accordance with Neurocrine Biosciences, Inc. (NBI) standards 
that meet regulations relating to Good Clinical Practice (GCP).  These standards respect the 
following guidelines:  
• Good Clinical Practice:  Consolidated Guideline (International Conference on 
Harmonis ation of Technical Requirements for the Registration of Pharmaceuticals for 
Human Use [ ICH; current version]). 
• United States (US) Code of Federal Regulations (CFR) dealing with clinical studies (21 CFR parts 50, 54, 56, 312, and 314). 
• Guidance for Clinical Trial Sponsors:  Clinical Trial Applications, Effective 29  May  2013, 
Health Canada Therapeutic Products Directorate, Health Products and Food Branch.  
The ethical requirements of Institutional Review Boards/Ethics Committees (IRBs/ECs) and the informed consent forms (ICFs) and assent forms are discussed in Section  14. 
5. INTRODUCTION  
5.1. Background 
Tourette syndrome (TS) is a movement disorder characterized by the presence of chronic motor 
and one or more vocal tics that often appear in childhood or early adolescence ( APA DSM -IV, 
1994;  APA DSM -V, 2013).  Tics are defined as rapid, non- rhythmic, stereotyped motor 
movements or vocalizations, and are typically categorized as simple or complex based on their overt features.  Simple tics are brief, meaningless actions (eg, forceful blinking of the eyes or grunting) and complex tics are slower, more purposeful behaviors (eg, gyrating or uttering phrases; Leckman et al., 1989;  Cavanna and Nani, 2013; Shprecher and Kurlan, 2009).  The tics 
follow a waxing and waning course over time, and must be recurrent for a period of more than 1 year to qualify for diagnosis.  In addition to tic phenomena, TS may also present with a 
constellation of symptoms that are part of a broader “TS spectrum,” which can include obsessive -compulsive behaviors, attention -deficit  hyperactivity disorder  (ADHD) , and 
impulsive or antisocial behavior ( Chen et al., 2012;  Felling and Singer, 2011). 
It has been well established that TS is predominantly a disorder of childhood with a mean or median age of onset of approximately 6 years of age ( Leckman et al. , 1998 ; Robertson, 2011;  
Jankovic and Kurlan, 2011;  Swain et al. , 2007).  Tic symptomatology usually becomes the most 
severe around age 10 and by the time adulthood is achieved at 18 years of age, mo st patients are 
either tic- free or their symptoms have significantly improved (Leckman et al., 1998 ; Kurlan, 
2010).  TS symptoms may also occur in adults and these tic phenomena appear to be a 
re-emergence or an exacerbation of childhood onset TS ( Chouinard and Ford, 2000;  Jankovic 
and Kurlan, 2011). 
Persistent tics can have a significant impact on patient quality of life and often lead to impaired 
psychosocial functioning.  Some of these problems include social isolation, bullying, physical discomf ort (with pain or injury), and poor academic performance (Roessner et al. , 2013).  
Psychosocial stressors can, in turn, exacerbate tic symptomatology.  It is under these conditions 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 16
that pharmacological interventions are often considered ( Chen et al., 2012; Shprecher and 
Kurlan, 2009;  Roessner et al., 2013). 
Neuropathological models have been proposed to explain the symptomatic features of TS, and 
converging lines of empirical evidence consistently implicate dopaminergic dysfunction and dysregulation within prefrontal cortex- basal ganglia circuitry ( Felling and Singer , 2011;  Pourfar 
et al., 2011).  Functional neuroimaging studies have identified a pattern of prefrontal cortex hypermetabolism and reduced striatal activity in TS patients ( Baxter and Guze, 1993;  Braun et  
al., 1993; Pourfar et al., 2011).  Pharmacotherapeutic approaches aimed at blocking postsynaptic dopamine-2 receptors (eg, haloperidol and pimozide) have demonstrated efficacy 
in reducing TS symptoms.  In this regard, modulation of dopaminergic tone through the administration of a vesicular monoamine transporter 2 (VMAT2 ) inhibitor, like NBI-98854, 
may also be an effective treatment option for tic suppression.  
5.2. NBI-98854 
NBI-98854 (valbenazine tosylate) is a selective, orally active VMAT2 inhibitor  developed by 
NBI.  NBI-98854 is under development for the treatment of TS.  NBI -98854 was approved by 
the US Food and Drug Administration (FDA ) in April 2017 for the treatment of adults with 
tardive dyskinesia (TD), under the trade name INGREZZA®. 
In nonc linical studies, NBI -98854 appears to cause little or no cytochrome P450 (CYP) enzyme 
inhibition or induction at pharmacologically relevant concentrations.  NBI -98854 is a moderate 
inhibitor of P-glycoprotein (P-gp), but only at concentrations that could be achieved in the gastrointestinal (GI) tract and  is not an inhibitor of a panel of other drug transporters.  
Metabolism of NBI -98854 is characterized by hydrolysis of NBI-98854 to NBI-98782, and 
CYP3A4/5-dependent mono- oxidation to NBI-136110.  NBI-98782 is metabolized in part by 
CYP2D6.  All 3 entities , namely, NBI-98854, NBI-98782, and NBI-136110, can  bind to and 
inhibit VMAT2.  However, NBI-98782 is the most potent and appears to be responsible for most  of the observed pharmacological activity of VMAT2 inhibition.  
NBI-98854 appears to be rapidly absorbed with a time to maximum plasma concentration (t
max) 
typically ranging from approximately 0.5 to 1.0 hours.  NBI- 98854 reaches steady state within 
1 week.  The active metabolite NBI -98782 gradually forms with a t max of 4 to 8 hours and both 
NBI-98854 and NBI- 98782 are eliminated with a terminal half -life (t ½) of 15 to 22 hours.  
Coadministration of ketoconazole (strong CYP3A4/5 inhibitor) with NBI-98854 led to a 1.5- and 1.6- fold increase in the maximum plasma concentration (C
max) of NBI-98854 and 
NBI-98782, respectively, and a 2.1- fold increase in the area under the plasma concentration 
versus time curve (AUC) from 0 hours extrapolated to infinity (AUC 0–∞) of NBI-98854 and 
NBI-98782.  Coadministration of NBI-98854 and rifampin (strong CYP3A4/5 inducer) le d to an 
approximate 30% and 70% decrease in C max and AUC 0–∞, respectively, for valbenazine, and an 
approximate 50% and 80% decrease, respectively, for NBI-98782 compared with administration of NBI-98854 alone.  Coadministration of NBI-98854 80 mg and 0.5 mg digoxin resulted in an 
approximate 1.9- fold increase in the C
max of digoxin.  The effect of NBI-98854 on digoxin 
AUC 0–∞ was modest ( 1.4-fold increase) and the mean t½ of digoxin was similar with and 
without NBI-98854 administration.  Midazolam Cmax and A UC 0–∞ were similar with and 
without NBI-98854 administration. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 17
NBI-98854 for the treatment of TS has been evaluated  in 3 completed Phase 1b and Phase 2 
studies in patients with TS.  These include 2 studies in pediatric subjects (NBI -98854-1403 and 
NBI-98854-1501) and 1 study in adults (NBI -98854-1505).  The initial Phase 1b, open -label, 
multiple- dose study of the safety, tolerability,  pharmacokinetics  (PK), and pharmacodynamics 
(PD) of NBI-98854 (NBI-98854-1403) was conducted in children (6 to 11 years of ag e) and 
adolescents (12 to 18 years of age) with TS .  Doses of NBI-98854 5 mg and 10 mg were 
administered in children and d oses of NBI-98854 10 mg, 25 mg, or 50 mg were administered in 
adolescents  daily over a 14 -day treatment period following a multiple as cending dose protocol.  
Study NBI-98854-1501 was a Phase 2, multicenter, randomized, double-blind, placebo-
controlled, parallel group, dose- ranging study to evaluate the efficacy, safety, and tolerability of 
2 doses of NBI-98854 (10 mg and 20 mg in children [6 to 11 years of age], and 20 mg and 
40 mg in adolescents [12 to 17 years of age]) relative to placebo, administered once daily  (qd) 
for 6 weeks in  98 pediatric subjects with TS.  Subjects within each age group were  randomized 
in a 1:1:1 ratio to placeb o or 1 of the 2 NBI-98854 doses.  Study NBI-98854-1505 was a Phase 
2, multicenter, randomized, double- blind, placebo- controlled, parallel group study to evaluate 
the efficacy, safety, and tolerability of 2 doses of NBI-98854 (40 mg and 80 mg) relative to placebo, administered qd for 8 weeks in 124 adult subjects with TS.  Subjects were  randomized 
in a 1:1:1 ratio to placebo or 1 of the 2 NBI-98854 doses.   
PD results from NBI-98854-1403 revealed reductions from baseline (Day -1) to Day 14 in the 
Yale Global Tic Severity Scale ( YGTSS ) total tic score (TTS) in both children and adolescents, 
and this decrease was observed irrespective of dose.  The mean point reduction in TTS for all 
subjects across all doses tested was -9.4 points at Day 14, which represents a 31% decrease 
from the mean baseline score.  Mean reductions from baseline were also observed in the YGTSS impairment score for both age groups.  The Phase 2, NBI-98854-1501 study in children 
and adolescents did not meet its primary efficacy endpoint of a significant change from baseline to Week 6 in the TTS between the placebo and active groups.  A comprehensive exposure-
response analysis indicated that the doses selected for this study were too low to provide adequate plasma exposures for tic reduction in most pediatric subjects.  For the subset of 
subjects with NBI-98854 exposures in the relevant range, there was a reduction in tics  
(range:  -11.3 to -13.7 points on the TTS) compared with  the subset of subjects with sub -
therapeutic exposures  (range:  -4.7 to -8.3 points on the TTS).  Although the efficacy results in 
participating adults in the NBI -98854-1505 study showed an improvement in overall symptoms 
of TS as measured  by the secondary endpoint, Clinical Global Impression of Change (p=0.015 
[nominal]), the prespecified primary endpoint, the change from baseline in the YGTSS  at Week 
8 was not met (p=0.18).   
NBI-98854 has been generally well tolerated in single doses up to 300 mg and in multiple doses 
of up to 100 mg in healthy volunteers and patients with TD.  Over 850 subjects have been 
exposed to NBI-98854 in TD clinical studies.  In TS patients, safety results from 
NBI-98854-1403 show that the doses were well tolerated in both child and adolescent age 
groups.  There were no deaths or serious adverse events (SAEs) reported during the study and no child discontinued due to an adverse event ( AE).  Two adolescents (both in the NBI -98854 
50 mg group) discontinued due to AEs.  One subject discontinued on Day 2 due to the AEs of agitation, headache, visual impairment, vomiting, and worsening of bradycardia and the other subject discontinued on Day 4 due to the AEs of increased anxiety and insomnia.   Preliminary 
safety results from the Phase 2, NBI-98854-1501 pediatric s tudy suggest that all doses tested 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 18
(NBI-98854 10 mg and 20 mg in children and NBI-98854 20 mg and 40 mg in adolescents) 
were well tolerated in these pediatric subjects with TS.  The most frequently reported AEs were 
headache, somnolence, upper respiratory tract infection, insomnia, and sedation.  There were no 
deaths and only one SAE in the placebo group (conversion disorder).  Preliminary results from NBI-98854-1505 showed that the most frequently reported AEs were somnolence (20.2% 
NBI-98854- treated subjects and 2.5% of placebo subjects), fatigue (14.3% NBI-98854 and 
2.5% placebo), and akathisia (13.1% NBI-98854 and 0% placebo).  Seventeen subjects (13.7%) discontinued from the study due to AEs, and most of these subjects received NBI-98854 80 mg (13/17 subjects) and the most common reason for AE discontinuation was akathisia (reported in 5 subjects).  Four subjects experienced SAEs during the study; the SAEs included pelvic inflammatory disease (placebo subject; moderate and not related to NBI -98854), pneumothorax 
(80 mg subject; moderate and unlikely related to NBI -98854), hypersensitivity (80 mg subject; 
moderate and possibly related to NBI -98854), and pneumonia streptococcal, septic shock, renal 
failure acute, and brachial plexus injury ( 40 mg subject; severe and unlikely related to 
NBI-98854).   
5.3. Study and Dose Rationale 
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose- optimization  study to 
evaluate the efficacy, safety, and tolerability of NBI -98854 titrated to the subject’s optima l dose 
in the range of 20 mg to 60 mg for subjects <50 kg and 40 mg to 80 mg for subjects ≥50 kg compared to placebo, administered qd for a total of 12 weeks of treatment in pediatric subjects 
with TS.  Subjects must have at least moderate current TS sympt oms, as defined  
by a Clinical Global Impression of Tics -Severity scale ( CGI-Tics-Severity ) score of ≥4 
(ie, moderately ill) at screening.  
Rationale for Dose Selection and Regimen  
Subjects will be randomized in a double-blind manner to qd doses of NBI-98854 for 12 weeks.  
For subjects randomized to active treatment, the starting dose will be NBI -98854 20 mg for 
subjects <50 kg and NBI-98854 40 mg for subjects ≥50 kg, which may be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects <50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of NBI-98854 for each subject. 
The current starting doses of NBI-98854 ( ie, 20 mg or 40 mg) have been well tolerated in 
previous studies in pediatric subjects with TS (NBI -98854-1403 and NBI-98854-1501).  The 
dose optimization  scheme based on efficacy, tolerability, and safety assessments , as well as  
bedtime dosing will allow subjects to potentially receive an optimal dose (ie, one that is both 
well tolerated and efficacious) during the treatment period.  Furthermore, the intermediate and 
high doses have been predicted to potentially  provide adequate plasma levels of NBI -98782 for 
a greater proportion of subjects to achieve clinically meaningful tic suppression based on 
exposure-response modeling.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 19
6. STUDY OBJECTIVES  
The objectives of this clinical study are as follows:  
Primary:  
• To evaluate the efficacy of NBI -98854, titrated to the subject’s optimal dose in the range 
of 20 mg to 60 mg for subjects <50 kg and 40 mg to 80 mg for subjects ≥50 kg, 
administered qd for the treatment of TS.  
Secondary:  
• To evaluate the safety and tolerability of NBI -98854, titrated to the subject’s optimal 
dose in the range of 20 mg to 60 mg for subjects <50 kg and 40 mg to 80 mg for subjects ≥50 kg, administered qd. 
• To evaluate plasma exposure measures of NBI -98854 and its active metabolite, 
NBI-98782, following titrated doses of NBI-98854 from 20 mg to 60 mg for subjects 
<50 kg and 40 mg to 80 mg for subjects ≥50 kg. 
7. OVERVIEW OF STUDY DESIGN  
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose- optimization study to 
evaluate the efficacy, safety, and tolerability of NBI -98854 titrated to the subject’s optimal dose 
in the range of 20 mg to 60 mg for subjects <50 kg at baseline and 40 mg to 80 mg for s ubjects 
≥50 kg at baseline compared to placebo, administered qd for a total of 12 weeks of treatment in pediatric subjects with TS.  Approximately 120 male and female pediatric subjects, 6 to 17 years of age, with a Diagnostic and Statistical Manual of Men tal Disorders, 4th or 5th Editions 
(DSM -IV or -V) diagnosis of TS will participate.  There will be an approximately equal 
distribution of subjects in each weight group, <50 kg and ≥50 kg, enrolled into the study and subjects will be stratified based on their weight.  Eligible subjects will be randomized in a 1:1 ratio to NBI -98854 or placebo treatment as shown in Table 1. 
Table 1: Treatment by Weight Group 
Weight Group  
 Assigned Treatment  Number of Subjects  
(approximate) 
Subjects <50 kg  at baseline  
 Placebo  30 
 NBI-98854 (20 to 60 mg)  30 
Subjects ≥50 kg at baseline  
 Placebo  30 
 NBI-98854 (40 to 80 mg)  30 
For subjects randomized to active treatment, the starting dose will be NBI -98854 20 mg for 
subjects <50 kg at baseline and NBI-98854 40 mg for subjects ≥50 kg at baseline, which may be 
escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects <50 kg 
and 80 mg for subjects ≥50 kg to achieve an optimal dose of NBI-98854 for each subject.  To 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 20
maintain the study blind, subjects randomized to placebo in each weight group will be subjected 
to the same dose escalation requirements , but will receive only placebo during the treatment 
period.  Dose escalations will occur at the end of Weeks 2 and 4 based on the following 2 criteria:  1) the subject’s tics are not sufficiently controlled per physician investigator 
assessment; and 2) an evaluation by the physician investigator indicates that the subject is tolerating the study drug at the current dose and would likely be able to tolerate the next dose level.  During the first 6 weeks of the 12-week double- blind treatment period,  the physician 
investigator may escalate a subject’s dose to the next dose level, continue with the subject’s current dose, or reduce to the subject’s prior tolerated dose (in subjects who have had a dose escalation).  After Week 6, subjects will continue to receive their optimized dose of NBI -98854 
or placebo for an additional 6- week dose maintenance period.  If a subject’s optimal dose has 
already been established at Week 2 (or at Week 4 ), no further dose escalation will be allowed 
during the dose optimization period and the subject will continue at that dose until the end of the 12- week treatment period.  At any time after Week 2, the physician investigator may 
decrease the dose to the previous dose for any subject who had a dose escalation and who  is 
unable to tolerate a given dose increase.  The subject will continue at that dose until the end of 
the 12- week treatment period.  The investigator may reduce the subject’s dose only one time.  
Subjects who are unable to tolerate the starting dose or resumption of the previous dose will be discontinued from the study.  Follow- up assessments will be conducted at the end of Week 14 
(2 weeks after the last dose of the study drug). 
After providing parental or legal guardian informed consent with signed and w itnessed pediatric 
assent, subjects will be screened to determine eligibility within 28 days (Days -28 to -1) before 
the start of study drug dosing on Day 1.  On Day 1 (baseline), eligible subjects will return to the 
study center for collection of baseline safety and efficacy assessments, and the collection of a blood sample for subsequent determination of their CYP2D6 metabolizer status.  Subjects who continue to be eligible for the study will then be randomized (1:1) to placebo or NBI-98854, with assigned  dose based on weight group at baseline.  A 2-week supply of study drug will be 
dispensed. 
Beginning on Day 1, study drug will be administered qd at home at the subject’s bedtime under 
the supervision of the subject’s parent/legal guardian.  Subjects will continue to self -administer 
the study drug daily at approximately the same time for the duration of the 12 -week treatment 
period.  Subjects will return to the study center at fixed intervals (end of Weeks 2, 4, 6, 8, 10, and 12) for study assessments and dispensing of study drug (Weeks 2, 4, 6, 8, and 10 only).  As much as possible, these study visits and the follow -up visit should occur at the same time as the 
Day 1 (baseline)  visit to standardize the time of day for the assessment of efficacy, safety, and  
plasma exposure.  A representative from the study center will call the subject or parent/legal guardian 3 to 7 days after the start of dosing to inquire about any study drug- related issues with 
respect to compliance or tolerability.  All subjects who comp lete the 12 -week treatment period 
will enter a 2 -week follow-up period with a follow- up visit at Week  14 (subjects who terminate 
early will have Week 14 assessments conducted).  Efficacy, safety, and study drug exposure will be assessed at scheduled times throughout the study.  The treatment period visits (Weeks 2, 
4, 6, 8, 10, and 12) and the follow- up visit (Week 14) will have a visit window of -2 or +3 days.  
An independent Data Safety Monitoring Board (DSMB) will periodically review ongoing clinical safety data to ensure the safety and well -being of the study subjects.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 21
Efficacy assessments for TS are the YGTSS  (primary), the CGI- TS-Improvement, 
CGI-Tics-Severity, the Premonitory Urge for Tics Scale (PUTS), and the Gilles de la Tourette 
Syndrome – Quality  of Life Scale for Children and Adolescents (C&A-GTS -QOL).  The 
YGTSS, PUTS, and C&A-GTS -QOL will be administered at screening, on Day 1 (baseline), 
and at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit or at early termination).  At screening 
and Day 1 (baseline), the CGI- Tics-Severity scale will be used, and then both the 
CGI-TS-Improvement and CGI- Tics-Severity will be used to rate the overall severity and 
improvement of tics at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study visit or at early termination). 
Safety assessments including AE monitoring, clinical laboratory tests (hematology, clinical 
chemistry, and urinalysis), vital sign measurements, physical examinations, 12 -lead 
electrocardiogram (ECG), Columbia- Suicide Severity Rating Scale (C -SSRS, C hildren’s 
Version), Children’s Depression Rating Scale - Revised (CDRS-R), the Children’s Yale-Brown 
Obsessive  Compulsive Scale (CY -BOCS), the Attention -Deficit Hyperactivity Disorder Rating 
Scale-5 :  Home Version (ADHD Rating Scale-5), and Extrapyramidal Symptom Rating Scale-
Abbreviated (ESRS-A) will also be collected at scheduled times throughout the study.  
Blood samples for plasma drug and metabolite concentration analyses will be at Day 1 
(baseline)  and at Weeks 2, 4, 6, 8, 10, 12, and 14 (final study v isit or at early termination).  
Subjects/caregivers will be asked to record and provide dosing times from the evening before 
the treatment period visits when PK samples are collected.  
A schematic of the study design is  shown in Figure 1. 
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 22
 
Figure 1: Study Design Schematic  
Week 
Screening Dose Optimization Period
4
-12
Follow -upFollow -up 
Period  / ET
<50 kg
≥50 kg6Dose Maintenance Period
8 12Screening Period
14
-28 Day 1
Randomization on Day 1
20 mg 
NBI-9885420 or 40 mg  
NBI-9885420 or 40 or 60 mg 
NBI-98854
Screening Placebo Placebo Placebo
Placebo Placebo Placebo
40 mg 
NBI-9885440 or 60 mg  
NBI-9885440 or 60 or 80 mg 
NBI-98854Placebo
Placebo
40 or 60 or 80 mg NBI -98854Follow -up10
 
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 23
8. STUDY POPULATION  
This study will be conducted in approximately 120 male and female pediatric subjects  (6 to 
17 years of age)  with a DSM -IV or -V diagnosis of TS.  A total of approximately 60 subjects 
<50 kg and approximately 60 subjects ≥50 kg will be enrolled into this study.  Subjects must 
meet all the inclusion criteria and none of the exclusion criteria to enter the study.  
8.1. Inclusion C riteria  
To participate in this study, subjects must meet the following criteria:  
1. Have documentation of written and witnessed pediatric assent from the subject and written 
informed consent from the subject’s parents or legal guardian.  
2. Be male or female, aged 6 to 17 years, inclusive.  
3. Be in good general health, as determined by medical history, physical examination, clinical laboratory assessments, and 12- lead ECG.  
4. Have a DSM -IV or -V diagnosis of TS. 
5. Have at least moderate current tic severity, as defined  by a  CGI -Tics-Severity score of ≥4 
(ie, moderately ill) at screening.  This determination must be independently confirmed by the external video reviewer using a video recording of the subject’s YGTSS assessment administered at the clinical site by a trained and certified rater.  
6. Have TS symptoms that cause marked distress or significant impairment in  school, 
occupational, and/or social function. 
7. Subjects must have a stable psychiatric status (such as TS spectrum diagnoses [eg, obsessive -compulsive disorder, ADHD]) as clinically determined by the investigator.  
8. If medications are being used to treat TS symptoms and/or TS spectrum diagnoses, subjects must be on stable doses of these medications for a minimum of 30 days before Day 1 (baseline), and the medication regimen is expected to remain stable throughout the study period.  The use of concomitant dopamine antagonists (eg, pimozide, haloperidol, aripiprazole) and/or tetrabenazine to treat TS symptoms is prohibited.  Other nondopaminergic tic suppression therapy (eg, clonidine, guanfacine) is allowed during the study period if the dose regimen has been stable for a minimum of 30 days before Day 1 (baseline). 
9. Subjects with stable medical conditions requiring medications that are not prohibited per protocol must be on stable doses of these medications for a minimum of 30 days before Day 1 (baseline), and the medication regimen is expected to remain stable throughout the 
study period. 
10. Subjects of childbearing potential must agree to use contraception consisten tly from 
screening until 30 days (females) or 90 days (males) after the last dose of study drug.  A female subject of childbearing potential is defined as a female capable of becoming pregnant, which includes subjects who have had their first menstrual cycle (ie, menarche) and are not surgically sterile (ie, bilateral oophorectomy, hysterectomy or bilateral tubal 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 24
ligation for at least 3 months prior to screening).  A male subject of childbearing potential is 
defined as a subject who has reached spermarche and has not been vasectomized for at least 3 months prior to screening.   
Acceptable methods of contraception include the following:  
• Condom with spermicide (cream, spray, foam, gel, suppository, or polymer film). 
• Diaphragm with spermicide (with or without condom). 
• Cervical cap with spermicide (with or without condom).  
• Vaginal sponge impregnated with spermicide used with a condom.  
• Intrauterine device (IUD).  
• Hormonal contraception being taken for at least 3 months prior to screening.  
Subjects who practice total abstinence from sexual intercourse as the preferred lifestyle are 
not required to use contraception (periodic abstinence is not acceptable).  
11. Female subjects of childbearing potential must have a negative serum β -human chorionic 
gonadotropin (β-hCG) pre gnancy test at screening and negative urine pregnancy test at 
Day 1 (baseline).  
12. Have a body weight (in kg) greater than or equal to the 5th percentile of his/her age- and gender- matched weight percentile at screening.  
13. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepines, phencyclidine, cocaine, opiates, or cannabinoids) at screening  (based on results from central laboratory) and Day 1 ( baseline; 
based on results from on- site urine drug screen kit ).  Subjects who are on stable doses of 
prescribed and supervised (not as needed [prn]) benzodiazepines, opiates, or psychostimulants (for subjects with comorbid ADHD) can participate in the study.  
14. Adolescent subjects (12 to 17 ye ars of age) must have a negative alcohol breath test at 
screening and Day 1 ( baseline).  
15. Be willing and able to adhere to the study regimen and study procedures described in the protocol and informed consent/assent forms, including all requirements at the study center and return for the follow- up visit.  
8.2. Exclusion Criteria  
Subjects will be excluded from the study if they:  
1. Have an unstable medical condition or chronic disease (including significant neurological, hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease), or 
malignancy that could confound interpretation of study outcome. 
2. Had a medically significant illness within 30 days of screening.  
3. Excessive use of tobacco and/or nicotine-containing products (based on t he investigator’s 
assessment) within 30 days of screening.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 25
4. Have a history of substance (drug or alcohol) dependence or abuse within the 3 months 
before Day 1 ( baseline), as defined in the DSM -IV (Substance Dependence or Abuse) or 
DSM -V (Substance Use Disor der). 
5. Are currently pregnant or lactating.  
6. Have a known history of neuroleptic malignant syndrome. 
7. Have a known history of long QT syndrome or cardiac arrhythmia. 
8. Have a screening or Day 1 average triplicate ECG corrected QT interval using Fridericia's formula (QTcF) of >450 msec or the presence of any clinically significant cardiac abnormality.  
9. Have serum creatinine levels greater than the upper limit of normal (ULN) at screening, or aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) , or total bilirubin  >1.5 times the ULN at screening.  Subjects with a 
documented diagnosis of Gilbert's syndrome are not required to meet the bilirubin criteria.  
10. Have any of the following hematologic abnormalities at screen ing: 
• Hemoglobin <11.0 g/dL. 
• White blood cell (WBC) count <4.0 × 10
3/mm3. 
• Platelet count <100,000/mm3. 
11. Have a hematologic malignancy or solid tumor diagnosed within 3 years prior to screening, except for localized skin cancer or carcinoma in situ of the cer vix. 
12. Have biochemistry or hematology not within the laboratory’s reference range and deemed by the investigator to be clinically significant at screening.  
13. Have a positive human immunodeficiency virus antibody (HIV -Ab) test result, hepatitis B 
surface antig en (HBsAg) test result, or hepatitis C virus antibody (HCV-Ab)  with  
confirmatory positive polymerase chain reaction reflex test result at screening.  
14. Have received any investigational product within a time period equal to 5 half -lives of the 
product, if known, or a minimum of 30 days before screening, whichever is longer, or plan to use an investigational drug (other than NBI-98854) during the study. 
15. Have received any excluded concomitant medication as detailed in Section  9.8.1.  
16. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at Day 1 ( baseline) or plan to initiate CBIT during the study.  
17. Have a blood loss ≥250 mL or donated blood within 56 days or donated plasma within 7 days of Day 1 ( baseline).  
18. Have a significant risk of suicidal or violent behavior.  Subjects with any lifetime suicidal behavior, or suicidal ideation of type 4 (active suicidal ideation  with some intent to act, 
without specific plan) or type 5 (active suicidal ideation with specific plan and intent) in the past year before screening based on the C-SSRS Children’s Version should be excluded. 
19. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors (eg, tetrabenazine).  
20. Have a history of or suspected poor compliance in clinical research studies.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 26
21. Have previous experience with NBI -98854 or previously participated in an NBI-98854 
clinical study.  
8.3. Subject Identification and Replacement  
Subjects will be identified by their unique subject number and initials (first, middle, last; a 
hyphen may be used if the subject has no middle name).  The subject initials and subject number will be noted on electronic case report forms (eCRFs), all source documentation, laboratory documents, and ECG tracings.  Subjects who discontinue from the study will not be replaced.  
8.4. Randomization 
An Interactive Web Response System (IWRS) will be used to randomize subjects to 1 of 
2 double-blind trea tment assignments within each weight  group:  placebo or NBI -98854 
(starting NBI -98854 dose of 20 m g in subjects <50 kg and 40 mg in subjects ≥50 kg) in a 1:1 
ratio.  Randomizat ion will occur on Day 1 after the subject is confirmed to have met the 
eligibility criteria.  Treatment assignments will be made per a computer -generated 
randomization schedule.  Investigators or a designee will access the IWRS to obtain randomization assignments.  
9. STUDY EVALUATIONS  
9.1. Schedule of Assessments  
A schedule of assessments that summarizes the frequency and timing of all assessments is provided in Table 2.  No protocol-related procedures should be performed before parental or legal guardian informed consent with written and witnessed pediatric assent have been obtained.  
Subject- related events  and activities including specific instructions, procedures, concomitant 
medications, dispensing of study drug, and descriptions of AEs should be recorded in the appropriate source documents and eCRFs. 
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 27
Table 2: Schedule of Assessments  
Procedurea Screening Period  Treatment Period  Follow -up Period  
Day 1b Dose Optimization  Dose Maintenance  Follow -up/ ET  
Week      Day -28 to -1 Baseline  Dosing  2 4 6 8 10 12 14c 
Visit  1 2 -- 3 4 5 6 7 8 9 
Informed consent/assent  X          
Treatment assignment script/videod X X         
Inclusion/exclusion criteria  X update          
Medical history  X update          
Physical examination (including  weight) X X  X  X   X X 
Height  X          
Vital signs  X X  X X X X X X X 
12-lead ECGe X X  X X X X X X X 
Pregnancy testf X (s)  X (u)  X (u)  X (u)  X (u)  X (u)  X (u)  X (u)  X (u)  
Serology (HBsAg, HCV -Ab and HIV -Ab) X          
Clinical laboratory testsg X X  X X X X X X X 
Urine drug screen (adolescents)  X X         
Alcohol breath test (adolescents)  X X         
Genotype blood sampleh  X         
Blood sample for prolactin   X  X X X X X X X 
Blood sample for PK assessments   X  X X X X X X X 
YGTSS (including video recording) X X  X X X X X X X 
PUTS X X  X X X X X X X 
CGI-Tics-Severity   X X  X X X X X X X 
CGI-TS-Improvement     X X X X X X X 
C-SSRS  X X  X X X X X X X 
CY-BOCS and CDRS -R X X  X X X X X X X 
ADHD Rating Scale -5: Home Version   X  X X X X X X X 
ESRS -A X X  X X X X X X X 
C&A -GTS -QOL  X X  X X X X X X X 
Randomization   X         
Study drug dosing at homei   X X X X X X X  
Dispense study drug   X  X X X X X   
Study drug accountabilityj    X X X X X X  
AE monitoring X X X X X X X X X X 
Prior and concomitant Medications X X X X X X X X X X 
Call to subjectk    X       
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 28
ADHD =attenti
on-deficit  hyperactivity disorder; AE =adverse event; C&A -GTS -QOL =Gilles de la Tourette Syndrome – Quality of Life Scale for Children and 
Adolescents; CDRS -R=Children’s Depression Rating Scale - Revised; CGI -Tics-Severity =Clinical Global Impression Tics -Severity scale; 
CGI-TS-Improvement =Clinical Global Impression of Tou rette Syndrome -Improvement scale; C -SSRS= Columbia -Suicide Severity Rating Scale; CY -
BOCS =Children’s Yale -Brown Obsessive Compulsive Scale; ECG =electrocardiogram; ESRS -A=Extrapyramidal Symptom Rating Scale -Abbreviated; ET =early 
termination; HBsAg =hepatitis B surface antigen; HCV -Ab=hepatitis C virus antibody; HIV -Ab=human immunodeficiency virus antibody; PK=pharmacokinetic; 
QTcF =corrected QT interval using Fridericia’s formula; PUTS =Premonitory Urge for Tics Scale; s =serum; u =urine; YGTSS =Yale Global Tic Se verity Scale.  
a As much as possible, study visits should occur at approximately the same time as the Day 1 visit to standardize the time of d ay for the assessment of efficacy, 
safety, and plasma exposure throughout the study period.  
b Day 1 is the day of baseline assessments and randomization.  Day 1 is also the first day of dosing; study drug will be admini stered at home at bedtime.  Vi sits 
will have a window of -2 to +3 days.  
c Final study visit for subjects who complete the study (or early termination).  
d Subjects w ill be shown the video titled “Your Role in a Clinical Trial, Some Information about Research Studies” (at screening only) and informed about the 
placebo -controlled design of the study using the treatment assignment script provided by the Sponsor (on Day 1 [baseline] only).  
e A standard 12- lead ECG will be conducted in triplicate ( at least 1 minute apart and within 15 minutes ) after the subject has rested supine for at least 5 minutes.  
The ECG pa rameters will be based on the ECG machine readings (QTcF may be calculated).  
f A serum pregnancy test will be conducted at screening and urine pregnancy tests will be conducted at all other study  visits for female subjects of childbearing 
potential.  
g Clinical laboratory tests include hematology, clinical chemistry and urinalysis.  All blood samples will be obtained under no nfasted condi tions.  
h Blood sample for genotyping will be analyzed for enrolled subjects only.  
i Study drug will be administered once daily at the subject’s bedtime at home under the supervision of their parent/guardian.  The date and time of each dosing of 
study drug will be recorded.  
j Subjects will return all used and unused study drug, and a compliance check will be performed by counting the capsules returned at each study visit.  
k Sites are to call subjects within 3 to 7 days from Day 1  to inquire about compliance or tolerabil ity issues.  
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 29
 
9.2. Screening and Baseline Assessments  
9.2.1. Genotyping  
On Day 1 (baseline), a blood sample will be collected from enrolled subjects for the analysis of 
CYP2D6 status (ie, normal , intermediate, poor, or ultra- rapid metabolizers).  Approximately 
4 mL of blood will be collected in tubes containing dipotassium ethylenediaminetetraacetic acid 
(EDTA K 2).  After the sample is obtained, it should be thoroughly mixed.  The vials will be 
stoppered and labeled with the study barcode and subject number.  The samples will be stored at 
approximately -20°C within approximately 15 minutes of collection.  The collection and 
submission of medical information will be accomplished with strict adherence to professional standards of confidentiality.  Genotyping blood samples collected from subjects will be shipped to a central laboratory for analysis.   
9.3. Efficacy Assessments  
9.3.1. Yale Global Tic Severity Scale  
The YGTSS will serve as the primary assessment of tic behaviors associated with TS ( Leckman  
et al., 1989).  The YGTSS is designed to rate the overall severity of motor and phonic tic 
symptoms across a range of dimensions:  number, frequency, intensity, complexity, and interference.  The scale also includes an impairment assessment.  The YGTSS will be 
administered by the investigator (or qualified designee) using a computer -based structured 
clinical interview.  At each timepoint, the YGTSS interview will be video recorded.  The video recording will follow a standardized set of guidelines and the recorded video will be uploaded  
to a secure central server.  An external video reviewer, not affiliated with the site,  will access 
the central server to view the recording and 1) confirm the subject’s TS severity is at least 
moderat e based on a CGI- Tics-Severity of ≥4 (at screening only), and 2) determine if the 
YGTSS interview program was administered properly.  The computer software system for the YGTSS administration, Rater  Station
™ (Bracket Global, LLC ; Philadelphia, PA), will prompt 
the investigator (or a qualified designee),  a trained and certified rater,  to enter a score for each 
item of the scale based on subject and parent responses during the structured clinical interview .  
As much as possible, a given subject should have the same rater throughout the study.  The 
software will also generate individual scores for each item of the scale (tandem rating) and will 
generate the TTS  and the Global Tic Severity Score.  
The YGTSS will be administered at screening, Day 1 (baseline) , Weeks 2, 4, 6, 8, 10, 12, and at 
the final follow- up visit (Week 14), or early termination.  A copy of the YGTSS is provided in 
Appendix 17.1.  
9.3.2. Premonitory Urge for Tics Scale  
The PUTS is a valid and reliable instrument for quantifying the premonitory urge phenomena 
associated with tics ( Woods et al., 2005).  Each of the 9 items in the PUTS is rated on a 4 -point 
scale (1=not at all true, 2=a littl e true, 3=pretty much true, 4=very much true) and summed to 
yield at a total score reflecting the presence and frequency of pretic (ie, premonitory) urges along with relief that may be experienced after tics have been completed.   
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 30
 
The investigator (or designee) will administer the PUTS at screening,  Day 1 (baseline) , 
Weeks  2, 4, 6, 8, 10, 12 and at the final follow -up visit (Week 14), or early termination.  A copy 
of the PUTS is provided in Appendix 17.2 . 
9.3.3. Clinical Global Impression Scales  
The CGI- Tics–Severity and CGI-TS–Improvement scales will be used to rate the subject’s 
overall severity of tics and overall improvement of TS.   
The CGI-Tics-Severity scale will be used to assess overall severity on a 7-point scale (range:   
1=normal, not at all ill to 7=among the most extremely ill patients) .  The CGI- Tics-Severity will 
be assessed by the investigator at screening, Day 1 (baseline) , Weeks 2, 4, 6, 8, 10, 12 and at the 
final follow- up visit (Week 14), or early termination.  A copy of the CGI- Tics-Severity scale is 
provided in Appendix 17.3.  
The CGI-TS–Improvement scale will be used to assess overall improvement since the initiation 
of study drug dosing on a 7 -point scale (range; 1=very much improved to 7=very much worse) .  
CGI-TS-Improvement scales will be assessed by the investigator at Week s 2, 4, 6, 8, 10, 12 and 
at the final follow -up visit (Week 14), or early termination.   A copy of the 
CGI-TS-Improvement scale is provided in Appendix 17.4.  
9.3.4. Gilles de la Tourette Syndrome- Quality of Life for Children and Adolescents  
The C&A -GTS -QOL  is a valid and reliable instrument to assess the quality of life in children 
and adolescents with TS (Cavanna et al., 2013).  It consists of 27 items and 4 subscales 
(psychological, physical, obsessive- compulsive, and cognitive).  Each item is rated across 5 
response options:  “Never,” “Rarely,” “Sometimes,” “Often,” and “Always.”  There are 2 
versions of this instrument:  1 version for children aged 6 to 12 years and 1 version for adolescents aged 13 to 18 years.  The C&A -GTS -QOL also includes a visual analog scale, 
assessing how satisfied the subject feels with his/her life (range of 0  to 100, with 100 
representing the greatest satisfaction).  
The subject will complete the C&A -GTS -QOL at screening, Day 1 (baseline) , Weeks 2, 4, 6, 8, 
10, 12 and at the final follow -up visit (Week 14), or early termination.  The subject can receive 
assistance filling out the questionnaire if needed.  Copies of both versions of the 
C&A-GTS -QOL are  provided in Appendix 17.5. 
9.4. Pharmacokinetic Evaluations  
Blood samples to evaluate plasma concentrations of NBI -98854 and the metabolite NBI -98782 
will be collected  at Day 1 (baseline)  and at Weeks 2, 4, 6, 8, 10, 12 and at the final follow -up 
visit (Week 14), or early termination.   The exact time of collection will be recorded on the 
eCRF.  
For each  plasma sample, approximately 2  mL of blood will be collected in tubes containing 
EDTA K 2.  Once obtained, the samples should be thoroughly mixed.  If the sample is not 
centrifuged immediately, the collection tube will be placed upright in a test tube rack and kept on crushed ice.  Within 1 hour of collection, samples will be centrifuged at approximately 2000 g for 10 minutes, preferably under refrigerated conditions (2 to  8°C).  The  separated 
plasma will be aspirated using a disposable pipette and then transferred in approximately equal 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 31
 
volumes into 2 vials.  The vials will be stoppered and labeled with the study barcode, subject 
number and primary or back -up sample designation (PK  A and PK B, respectively) .  The 
samples will be stored at approximately -20°C within approximately 15 minutes of 
centrifugation.  The date and actual 24 -hour clock time of each collection will be recorded on 
the eCRF.  The duplicate plasma sample at each ti mepoint will be stored and used as backup.  
These samples (including a manifest with additional information) will be shipped to a central 
laboratory for analysis to be stored at approximately  -70°C.  Plasma samples remaining at the 
end of the study may be used for exploratory assessments. 
9.5. Safety Assessments  
Concomitant medication use and AEs will be monitored throughout the study as described in Section  9.8.1 and Section  11, respectively.  Additional safety assessments are described in the 
following sections.  
Any abnormal vital sign measurement, physical examination finding, clinical laboratory test, or ECG parameter deemed clinically significant by the investigator will be repeated, including test results obtained at the final study visit or upon early termination, until the value returns to baseline (or within normal limits), or the investigator deems the abnormality to be of no clinical significance.  If the investigator determines that a subject has a clinically significant finding of treatment -emergent depression, suicidal ideation, psychiatric symptoms (based upon the 
C-SSRS, CDRS-R, CY-BOCS, ADHD  Rating Scale-5, or clinical assessment), the finding will 
be documented as an AE, and appropriate psychiatric evaluation and intervention will be provided. 
9.5.1. Data Safety Monitoring Board 
An independent DSMB will periodically review ongoing unblinded clinical safety data to 
ensure the safety and well -being of the study subjects.  The safety data review may result in 
recommendation for early termination of the study or changes to the protocol and informed 
consent based on unexpected adverse findings.  A DSMB charter will describe the responsibilities, timing of meetings, and data review procedures for the members to follow.  
9.5.2. Vital Sign Measurements  
Vital signs will include orthostatic systolic and diastolic blood pressure, orthostatic pulse rate, respiratory rate (recorded only supine), and oral body temperature.  Blood pressure will be measured using a calibrated automatic blood pressure cuff after the subject has been supine for at least 5 mi nutes and after approximately 2 minutes of standing.  The automatic blood pressure 
cuff will also provide pulse rate measurement.  
Vital sign measurements will be collected at screening, Day 1 (baseline) , Weeks 2, 4, 6, 8, 10, 
12, and at the final follow -up visit (Week 14), or early termination.  Vital sign measurements 
will be obtained before any scheduled blood sample collection . 
9.5.3. Medical History  
A medical history will be taken at the screening visit and updated on Day  1.  The age at TS 
diagnosis will be documented for all subjects; if necessary, subject age at TS onset can be estimated by the investigator based upon available clinical information.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 32
 
9.5.4. Physical Examination, Including Height and Weight  
The complete physical examination will consist of an assessment of general appearance, skin 
and mucosae, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest/lungs, cardiovascular, abdomen, extremities, musculoskeletal, and neurological system.  A complete physical examination including weight will be performed at screening, Day 1 (baseline) , and at 
Weeks 2, 6, 12, and at the final follow -up visit (Week 14), or early termination.   Height will be 
measured at screening only.  Height and weight will be measured with subjects not wearing shoes.  
9.5.5. Electrocardiogram  
A standard 12- lead ECG will be recorded in triplicate (at least 1 minute apart  and within 
15 minutes) after the subject has rested supine for at least 5 minutes.  The ECG parameters that will be assessed include heart rate, PR interval, QRS duration, corrected  QT interval, and QTcF 
(machine readings or calculated).  Additionally, the occurrence of de- and re-polarization and rhythm disorders or other cardiac abnormalities will be assessed.  Based on the review of these parameters, the investigator or designee will note if the ECG is Normal, Abnormal not Clinically Significant, or Abnormal Clinically Significant.  If the ECG is Abnormal Clinically Significant, the investigator or designee will provide a description of the abnormality recorded on the AE eCRF. 
The 12- lead ECG recordings will be conducted at screening, Day 1 (baseline) , and at Weeks 2, 
4, 6, 8, 10, 12 and at the final follow -up visit (Week 14), or early termination.  
9.5.6. Clinical Laboratory Assessments  
All clinical laboratory assessments will be performed by a central laboratory, which will 
provide instructions and supplies to the study staff before study initiation.  The instructions will be included in a laboratory manual.  The laboratory test battery will include routine and 
screening laboratory tests.  Laboratory samples will be collected in the following approximate amounts:  Children (6 to 11 years of age) – 3 mL for hematology and 2.5 mL for clinical  
chemistry; adolescents (12 to 17 years of age) – 4 mL for hematology and 5 mL for clinical 
chemistry (includes screening serum pregnancy tests for female subjects of childbearing potential).  
Clinical safety laboratory assessments will be performed at screening, Day 1 (baseline), and at 
Weeks 2, 4, 6, 8, 10, 12, and at the final follow -up visit (Week 14), or early termination.  There 
are no fasting requirements for laboratory assessments.  
The following clinical safety laboratory assays will be performed:  
Hematology :  complete blood count including WBC count with differential, red blood cell 
count, hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), red cell distribution width  (RDW), and mean platelet volume (MPV).  
Clinical Chemistry :  sodium, potassium, calcium, magnesium, chloride, blood urea nitrogen, 
bicarbonate, creatinine, uric acid, albumin, alkaline phosphatase, lactate dehydrogenase, ALT, AST, GGT, creatine kinase, total bilirubin, total cholesterol, triglycerides, total protein , and 
glucose.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 33
 
Urinalysis :  specific gravity, nitrites, ketones, protein, urobilinogen, glucose, bilirubin, 
leukocyte esterase, occult blood, and pH; microscopic examination of sediment will be 
performed only if the results of the urinalysis dipstick evaluation are positive for nitrites, protein, leukocyte esterase, or blood. 
The following additional laboratory tests will be performed:  
Serum Prolactin:  Blood samples to determine serum prolactin concentration will be collected at 
Day 1 (baseline), at Weeks 2, 6, 8, 10, 12 and at the final follow -up visit (Week 14), or early 
termination.   Approximately 2.5 mL ( children, 6 to 11 years of age) or 5 mL ( adolescents, 12 to 
17 years of age ) of blood will be collected into a serum separator tube.  Serum prolactin samples 
will be shipped to a central laboratory for analysis.   Prolactin results will remain blinded to the 
investigator.  
Serology :  Blood will be co llected for HIV -Ab, HBsAg, and HCV -Ab testing at screening (as 
part of clinical chemistry).  The results of the anti-HIV -Ab testing will be retained by the study 
site under confidential restriction.  The following approximate amounts will be collected:  9  mL 
(children, 6 to 11 years of age) or 10 mL ( adolescents, 12 to 17 years of age). 
Urine Drug Screen and Alcohol Breath T est:  The urine drug screen will test for amphetamines , 
barbiturates, phencyclidine, benzodiazepines, cannabinoids, cocaine, and opiate s.  Urine testing 
kits will be provided by the central laboratory for preliminary confirmation of negative drug 
screen  at the site prior to dosing.  A separate urine sample will also be sent to the central 
laboratory for analysis.  A urine drug screen and alcohol breathalyzer test will be performed at screening and on Day 1.  The urine drug screen and alcohol breathalyzer test will be performed only in adolescent subjects (12 to  17 years of age).  A urine drug screen using a kit provided by 
the central labo ratory may be conducted at the clinical site at any time during the study if the 
subject (adolescent subjects only) is suspected of substance or drug abuse. 
Pregnancy Tests:  A pregnancy test will be conducted for female subjects of childbearing 
potential.   A serum pregnancy test will be conducted at screening and a urine pregnancy test 
will be conducted on Day  1, Weeks 2, 4, 6, 8, 10, 12 and at the final follow -up visit (Week 14), 
or early termination.  
9.5.7. Columbia -Suicide Severity Rating Scale Children’s Versions  
The C -SSRS is a validated instrument to prospectively assess suicidal ideation and behavior 
(http://www.cssrs.columbia.edu).  There are versions of the questionnaire designed for use at screening ( Children’s Baseline/Screening version) and at baseline and visits throughout the 
study ( Children’s Since Last Visit version).  All versions of the C -SSRS include a series of 
screening questions related to suicidal ideation and suicidal behavior.  Subject responses of “yes” to one or more screening questions will prompt additional questions that evaluate 
frequency and intensity of suicidal ideation and/or behavior.  Subjects with any lifetime suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type  5 (active suicidal ideation with specific plan and intent) in the 1 year 
before screening based on the C- SSRS Children’s version should be excluded (see exclusion 
criterion # 18 in  Section  8.2). 
The C -SSRS will be administered and scored by the investigator or qualified study center 
personnel at screening, Day 1 (baseline) , and Weeks 2, 4, 6, 8, 10, 12 and at the final follow -up 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 34
 
visit (Week 14), or early termination.   A copy  of each Children’s version of the C- SSRS is 
provided in Appendix 17.6 and Appendix 17.7,  respectively.  
9.5.8. Children’s Depression Rating Scale-Revised  
The CDRS-R is a 17- item, semi -structured interview to determine the severity of depression in 
children.  The investigator (or designee) will administer the CDRS -R at screening, Day 1 
(baseline) , and at Weeks 2, 4, 6, 8, 10, 12 and at t he final follow- up visit (Week  14), or early 
termination.   A copy of the CDRS-R is provided in Appendix 17.8.  
9.5.9. Children’s Yale-Brown Obsessive  Compulsive Scale  
The CY-BOCS is a semi -structured interview designed to rate the severity of obsessive and 
compulsive symptoms in children.  The investigator (or designee) will administer the 
CY-BOCS at screening, Day 1 (baseline) , Weeks 2, 4, 6, 8, 10, 12, and at the final follow -up 
visit (Week  14), or early termination.   A copy of the CY-BOCS is provided in Appendix 17.9. 
9.5.10. Attention- Deficit Hyperactivity Disorder Rating Scale-5:  Home Version  
The ADHD Rating Scale-5 :  Home Version will be used to determine the frequency and 
severity of ADHD symptoms and impairments over the past 2 weeks.   The scale comes in 
2 versions:  child (ages 5 to 10 years) and adolescent (ages 11  to 17 years).  Both versions 
consist of 2 symptom subscales, Inattention (9 items) , and Hyperactivity –Impulsivity (9 items), 
as well as a Total Scale (18 items).  In addition, 6 domains of impairment that are common 
among children with ADHD are assessed:   relationships with significant others (family 
members for the home version and teachers for the school version), peer relationships, academic functioning, behavioral functioning, homework performance, and self- esteem.    
It will be completed independently by the subject’s parent or guardian at Day 1 (baseline) , 
Weeks 2, 4, 6, 8, 10, 12 and at the final follow -up visit (Week 14), or early termination.  A copy 
of the ADHD Rating Scale-5 :  Home Version is provided in Appendix 17.10. 
9.5.11. Extrapyramidal Symptom Rating Scale-Abbreviated  
The ESRS -A is a psychometrically validated instrument that assesses 4  types of movement 
disorders:  parkinsonism, akathisia, dystonia, and dys kinesia (Chouinard and Margolese, 2005).  
The investigator (or designee) will administer the ESRS -A at screening, Day  1 (baseline) , 
Weeks  2, 4, 6, 8, 10, 12 and at the final follow- up visit (Week  14) or upon early termination.  A 
copy of the ESRS-A is provided in Appendix 17.11.  
9.5.12. Estimated Total Blood Sample Volume Required by Study 
The estimated total blood sample volume for each subject is presented in  Table 3.  These 
estimates include samples to be collected during screening, the treatment period, and the final 
visit ( Week 14 or upon early termination). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 35
 
Table 3: Estimated Total Blood Sample Volume 
Parameter  Number of Samples 
Required  Approximate  
Volume (mL)  Approximate Total 
Volume (mL)  
Children (6 to 11 years of age)  
Clinical chemistrya 9 2.5 22.5 
Hematology  9 3 27 
Genotyping  1 4 4 
Serology  1 9 9 
Serum prolactin  8 2.5 20 
Pharmacokinetics  8 2 16 
Approximate Maximum Total Blood Sample Volume per Subject (mL):  98.5 
Adolescents (12 to 17 years of age)  
Clinical chemistrya 9 5 45 
Hematology  9 4 36 
Genotyping  1 4 4 
Serology  1 10 10 
Serum prolactin  8 5 40 
Pharmacokinetics  8 2 16 
Approximate Maximum Total Blood Sample Volume per Subject (mL):  151 
a Includes pregnancy test for female subjects who are of childbearing potential at screening.  
9.6. Specific Study Information  
After providing parental or legal guardian informed consent with signed and witnessed pediatric 
assent (as required by the governing IRB), subjects will undergo screening procedures within 28 days of Day -1. 
9.6.1. Screening  (Days  -28 to -1) 
During screening, t he following study evaluations and tasks will be performed at the study 
center : 
• Obtain informed consent/ pediatric assent.  
• Subjects will be shown the video titled “Your  Role in a Clinical Trial , Some Information 
About Research Studies.” 
• Assess inclusion/exclusion criteria.  
• Collect medical history.  
• Perform a physical examination (including height and weight).  
• Collect vital signs, including orthostatic systolic and diastol ic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature.  
• Perform 12- lead ECG in triplicate (at least 1 minute apart and within 15  minutes ). 
• Perform a serum pregnancy test (β-hCG) only for female subjects of childbearing potential.  
• Collect blood sample for serology testing (HIV-Ab, HBsAg, and HCV -Ab). 
• Collect blood sample for hematology and clinical chemistry . 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 36
 
• Collect urine sample for urinalysis.  
• Perform alcohol breathalyzer test and urine drug screen (both only in adolesc ent subjects).  
• Administer the YGTSS , including video recording. 
• Administer the PUTS.  
• Administer the CGI -Tics-Severity scale. 
• Administer the C -SSRS (Children’s Screening/Baseline version). 
• Administer  the CY-BOCS and CDRS-R. 
• Administer the ESRS -A. 
• Administer  the C&A -GTS -QOL . 
• AE monitoring. 
• Record prior medications. 
All screening procedures must be completed , and results must be evaluated by the investigator 
before the baseline procedures are performed on Day 1. 
The following items will also be conducted at screening: 
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in  Section  8.1). 
• Eligible subjects will be instructed to return to the center on Day 1.   The following should 
be considered for scheduling purposes:  a s much as possible, visits should occur at 
approximately the same time as the Day 1 (baseline)  visit to  standardize the time of day for 
the assessment of efficacy, safety, and plasma exposure throughout the study period.  
9.6.2. Day 1  (Baseline Assessments and Start of Dosing)  
Subjects  and parents/legal guardians  will return to the center  on Day 1. 
On Day 1, the following baseline study evaluations and tasks w ill be performed  at the study 
center : 
• Subjects will be informed about the placebo -controlled design of the study using the 
treatment assignment script provided by the Sponsor. 
• Update inclusion and exclusion criteria. 
• Update medical history.  
• Perform a physical examination including  weight.  
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature.  
• Perform 12- lead ECG in triplicate (at least 1 minute apart and within 15  minutes ). 
• Perform a urine pregnancy test only for female subjects of childbearing potential.  
• Collect blood sample for hematology and clinical chemistry.  
• Collect urine sample for urinalysis.  
• Perform alcohol breathalyzer test and urine drug screen (both only in adolescent subjects).  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 37
 
• Collect blood sample for CYP2D6 genotype status (for randomized subjects only). 
• Collect blood sample for serum prolactin.  
• Collect PK blood sample for NBI-98854 and metabolite conce ntrations.  
• Administer the YGTSS , including video recording. 
• Administer the PUTS.  
• Administer the CGI -Tics-Severity scale. 
• Administer the C -SSRS ( Children’s Since Last Visit version ). 
• Administer  the CY-BOCS and CDRS-R. 
• Administer the ADHD Rating Scale-5. 
• Adm inister the ESRS -A. 
• Administer the C&A -GTS -QOL.  
• Access the IWRS to obtain randomization assignments for eligible subjects.  
• Dispense a 2 -week supply of study drug and provide instructions on storage and 
administration of the study drug. 
• Instruct subjects to  record the date and time of each dose on the labels provided on the study 
drug kit packaging form. 
• Instruct subjects to begin taking  study drug nightly at bedtime under supervision of their 
parents/legal guardians , beginning on Day 1.  (The timing of study drug administration 
should remain consistent throughout the treatment period.) 
• Instruct subjects and parents/legal guardians to return to the study center at Week  2 (-2 to  
+3 days)  and to bring their study drug kit. 
• AE monitoring. 
• Record concomitant medications.  
The following will also be conducted before subjects may leave the study center:  
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in  Section  8.1). 
• Instruct subjects and parents/legal guardians to notify the investigator by telephone if they 
experience any AEs and before taking any  new concomitant medications.  
Sites are to call subjects within 3 to 7 days  after the Day 1 visit  to inquire about compliance or 
tolerability issues.   Note, subsequent study visits will be 14 days from the previous visit; for 
example, the Week 2 visit will be on Day 15 (-2 to +3 days) and the Week 4 visit will be on 
Day 29 (-2 to +3 days). 
9.6.3. Dose Optimization Period:  Weeks 2, 4, and 6  (-2 to + 3 Days for Each Visit) 
Subjects and parents/legal guardians will r eturn to the study center at Weeks  2, 4, and 6. 
The fol lowing study evaluations and tasks  will be performed  at the study center : 
• Perform a physical examination including  weight (Weeks 2 and 6 only). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 38
 
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature. 
• Perform 12- lead ECG in triplicate (at least 1 minute apart and within 15  minutes ). 
• Perform a urine pregnancy test only for female subjects of childbearing potential.  
• Collect blood sample for hematology and clinical chemistry .  
• Collect urine sample for urinalysis.  
• Collect blood sample for serum prolactin.  
• Collect PK blood sample for NBI-98854 and metabolite concentrations. 
• Administer the YGTSS , including video recording. 
• Administer the PUTS.  
• Administer the CGI -Tics-Severity scale. 
• Administer the CGI-TS-Improvement scale.  
• Administer the C -SSRS ( Children’s Since Last Visit version ). 
• Administer  the CY-BOCS and CDRS-R. 
• Administer the ADHD Rating Scale-5. 
• Administer the ESRS -A. 
• Administer the C&A -GTS -QOL.  
• Perform compliance check by counting the capsules returned.  
• AE monitoring. 
• Record concomitant medications.  
Dose Escalation Assessment  
At the end of Week 2 and Week 4 visits, a dose escalation will occur  based on the following 2 
criteria:  1) the subject’s tics are not sufficiently controlled per physician investigator 
assessment; and 2) an evaluation by the physician investigator indicates that the subject is 
tolerating the study drug at the current dose and would likely be able to tolerate the next dose level.  Based on these criteria, the physician investigator will choose 1 of the following dosing 
options: 
• Dose escalation, which will occur in 20 mg increments ( to maintain the study blind, subjects 
randomized to placebo will be subjected to the same dose escalation requirements but will 
receive only placebo during the treatment period):  
− Subjects <50 kg at baseline:  from 20 mg to 40 mg (Week 2); from 40 mg to 60 mg (Week  4). 
− Subjects ≥50 kg at baseline:  from 40 mg to 60 mg (Week 2); from 60 mg to 80 mg 
(Week  4). 
• Maintenance of current dose (with no further dose increases). 
• Dose reduction to previous dose in subjects who have had a dose escalation.  The physician 
investigator may decrease the dose to the previous dose at any time after the end of Week 2 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 39
 
(including between scheduled study visits) for any subject who is unable to tolerate a given 
dose increase.  Subjects will receive this dose for the remainder of the treatment period.  
Once a determination of dose escalation, maintenance, or reduction is made, the IWRS  will be 
accessed to obtain an identification number for a kit containing a 2 -week supply of study drug 
to be dispensed to the subject.  The subject will remain blinded to dose escalations made during the treatment period; however, the investigator may inform the subject that a dose adjustment is possible if the subject is unable to tolerate a given dose increase.  
The following will also be conducted before subjects may leave the study center:  
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in  Section  8.1). 
• Instruct subjects and parents/legal guardians to notify the investigator by telephone if they 
experience any AEs and before taking any new concomitant medications.  
• Instruct subjects to record the date and time of each dose on the labels provided on the stu dy 
drug packaging form. 
9.6.4. Dose Maintenance Period:  Weeks 8, 10, and 12 (-2 to +3 D ays for Each Visit) 
At Weeks 8, 10, and 12 the following study evaluations and tasks  will be performed at the study 
center:  
• Perform a physical examination including weight (Week 12 only). 
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature.  
• Perform 12- lead ECG in triplicate (at least 1 minute apart and within 15  minutes ). 
• Perform a uri ne pregnancy test only for female subjects of childbearing potential.  
• Collect blood sample for hematology and clinical chemistry.  
• Collect urine sample for urinalysis.  
• Collect blood sample for serum prolactin.  
• Collect PK blood sample for NBI-98854 and meta bolite concentrations.  
• Administer the YGTSS, including video recording.  
• Administer the PUTS.  
• Administer the CGI -Tics–Severity scale. 
• Administer the CGI -TS–Improvement scale.  
• Administer the C -SSRS (Children’s Since Last Visit version). 
• Administer the CY -BOC S and CDRS-R. 
• Administer the ADHD Rating Scale-5. 
• Administer the ESRS -A. 
• Administer the C&A -GTS -QOL.  
• Dispense a 2 -week supply of study drug (Weeks 8 and 10 only). 
• Perform compliance check by counting the capsules returned.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 40
 
• AE monitoring. 
• Record concomitant medications.  
The following will also be conducted before subjects may leave the study center:  
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in  Section  8.1). 
• Instruct subjects and parents/legal guardians to notify the investigator by telephone if they experience any AEs and before taking any new concomitant medications.  
• Instruct subjects to record the date and time of each dose on the labels provided on the study drug packaging form. 
9.6.5. Follow -Up Period /Early Termination:  Week 14 (-2 to +3 Days) 
At Week 14 (or upon early termination) the following study evaluations and tasks  will be 
performed at the study center:  
• Perform a physical examination including  weight.  
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic pulse rate, respiratory rate, and body temperature.  
• Perform 12- lead ECG in triplicate (at least 1 minute apart and within 15  minutes ). 
• Perform a urine pregnancy test only for female subjects of childbearing potential.  
• Collect blood sample for hematology and clinical chemistry.  
• Collect urine sample for uri nalysis.  
• Collect blood sample for serum prolactin.  
• Collect PK blood sample for NBI-98854 and metabolite concentrations. 
• Administer the YGTSS , including video recording. 
• Administer the PUTS.  
• Administer the CGI -Tics–Severity scale. 
• Administer the CGI-TS–Improvement scale.  
• Administer the C -SSRS ( Children’s Since Last Visit version ). 
• Administer  the CY-BOCS and CDRS-R. 
• Administer the ADHD Rating Scale-5. 
• Administer the ESRS -A. 
• Administer the C&A -GTS -QOL.  
• AE monitoring. 
• Record concomitant medications.  
9.7. Study Duration 
The expected duration of study participation for each subject is approximately 18 weeks, 
including up to 28 days of screening, a 12- week , double-blind treatment period, and 2 weeks of 
follow-up, or early termination. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 41
 
9.8. Prohibitions and Restric tions  
9.8.1. Prior and Concomitant Medications  
All prescription and over the counter medications, including dietary and herbal supplements, 
taken by subjects during the 30 days before baseline (Day 1) and during the study will be 
entered on the Prior and Concomitant Medications eCRF.  Any additions, deletions, or changes in the dose of these medications will be entered on the eCRF with indication, dose, route, and dates of drug administration. 
The following medications are prohibited from 14 days before Day 1 (baseline) (unless 
otherwise stated) until the final study visit (or upon early termination) as described below:  
• Antiemetics:  Metoclopramide, prochlorperazine, and promethazine.  
• Botulinum toxin:  Botulinum toxin injections for treatment of TS are prohibited starting 
90 days prior to Day 1 (baseline) . 
• CYP3A4 inducers:  Strong inducers of CYP3A4 (eg, phenytoin, phenobarbital, rifabutin, rifampin, primidone, St. John's Wort, carbamazepine). 
• CYP3A4 inhibitors:  Strong inhibitors of CYP3A4 (eg, itraconazole, ketoconazole, 
clarithromycin).  
• Dopamine agonists and precursors:  Dopamine agonists (eg, ropinirole) and precursors 
(eg, carbidopa/levodopa). 
• Dopamine antagonist:  Dopamine antagonists (eg, pimozide, haloperidol, aripiprazole, 
risperidone, clozapine, olanzapine, ziprasidone) are prohibited.  Depot neuroleptics are prohibited starting 15 weeks prior to Day 1 (baseline) . 
• Monoamine oxidase inhibitors (MAOIs):  All MAOIs (eg, isocarboxazid, phenelzine, 
selegiline, tranylcypromine).  
• VMAT2 inhibitors:  VMAT2 inhibitor medications (eg, tetrabenazine, reserpine), except for 
study drug. 
• As needed use of the following medications:   anticholinergics, benzodiazepines, 
antipsychotics, psychostimulants, mood stabilizers, antidepressants, opiates, and strong CYP2D6 inhibitors.   
9.8.2. Dietary Restrictions  
Subjects are not permitted to consume more than 6 caffeine- containing beverages a day.  
Grapefruit juice or grapefruit products are prohibited from 7 days before Day 1 until the 
follow-up visit.  Alcohol is prohibited from 48 hours before Day 1 until the follow-up visit. 
9.8.3. Other Restrictions  
Excessive use of tobacco and other products containing nicotine (including nicotine gum and patches) are prohibited during the study (ie, from 30 days before screening to the follow- up visit  
or upon early termination ).  Strenuous activity beyond what is customary for the subject is 
prohibited during the study.  Subjects must agree not to donate blood during the study, including the screening period, and for 4 weeks after completion of the study. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 42
 
Subjects must not have initiated CBIT during the screening period or at Day 1 (baseline)  or plan 
to initiate CBIT during the study.  
9.9. Withdrawal Criteria  
Subjects are free to discontinue their participation in the study at any time.  The investigator 
must withdraw any subject from the study if that subject requests to be withdrawn.  
The investigator must withdraw the subject from the study if the subject experiences any of the following: 
• If the type, frequency, or severity of any AE becomes unacceptable/intolerable.  
• If the subject is unable to tolerate the starting dose or resumption of the previous dose.   
• QTcF value >500 msec (cardiologist verified).  
• If the subject exhibits suicidal behavior, or suicidal ideation of type 4 (active suicidal 
ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation 
with specific plan and intent) based on the C -SSRS.  
• Is lost to follow-up. 
• Subject is confirmed to be pregnant.  
The investigator or NBI may withdraw  the subject from the study for other reasons as described 
below.  These should be discussed on a case- by-case basis with the NBI medical monitor (or 
designee) prior to withdrawing the subject from the study. 
• Develops a clinically significant laboratory (e g, ALT or AST ≥2.5 times ULN) or ECG 
abnormality.  
• Requires a medication that is prohibited by the protocol (refer to Section  9.8.1). 
• Is non- complian t with the dosing regimen (<80% dosing compliance) as verified by drug 
accountability ( refer to Section  10.6). 
All subjects prematurely discontinuing the study, regardless of cause, must have all early 
termination assessments performed (see Section  9.6.5). 
9.9.1. Handling of Withdrawals 
If a subject prematurely withdraws from the study, either at his/her request, at the request of the parent or legal guardian, or at the investigator’s discretion, the investigator will record the reason for withdrawal on the relevant eCRF.  All subjects who withdraw from the study prematurely must have all early termination assessments performed.  
It is crucial to obtain follow -up data for any subject withdrawn because of an AE, abnormal 
laboratory test, vital sign measurement, physical examination,  or ECG finding.  In any case, 
every effort must be made to undertake safety follow -up procedures. 
9.9.2. Sponsor’s Termination of Study 
NBI reserves the right to discontinue the study at any time for clinical or administrative reasons.  
Such a termination must be implemented by the investigator, if instructed to do so by NBI in a time frame that is compatible with the subjects’ well -being. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 43
 
10. STUDY DRUG  
10.1. Study Drug Supplies  
NBI or its desi gnee will provide the study centers with subject -specific study drug kits sufficient 
for the completion of the treatment period of the study. 
NBI-98854 will be supplied as capsules containing 20 or 40 mg  of NBI-98854 (free base 
equivalent ).  The NBI -98854 20 and 40 mg capsules are a white, opaque, hydroxypropyl 
methylcellulose ( HPMC ) No. 3 size capsule containing 20 and 40 mg, respectively  of 
NBI-98854 (dose is of the free base) and is form ulated using Capsugel shells .   
The matching placebo capsules are identical in appearance to the NBI -98854 capsules. 
All subjects will receive the starting dose of study drug beginning on Day 1.  At Weeks 2 and 4, 
subjects may have their dose increased based on protocol- specified efficacy and safety criteria.  
Dosing information is provided below.   Subjects <50 kg at baseline:  
• Starting dose:  20 mg NBI-98854 (one 20 mg capsule and one placebo capsule) or 
placebo (2 capsules) 
• Week 2:  40 mg NBI-98854 (two 20 mg capsules) or placebo (2 capsules) 
• Week 4:  60 mg NBI-98854 (one 20 mg and one 40 mg capsule) or placebo (2 capsules) 
Subjects ≥50 kg at baseline:  
• Starting dose:  40 mg NBI-98854 (two 20 mg capsules) or placebo (2 capsules) 
• Week 2:  60 mg NBI-98854 (one 20 mg and one 40 mg capsule) or placebo (2 capsules) 
• Week 4:  80 mg NBI-98854 (two 40 mg capsules) or placebo (2 capsules) 
If a subject’s optimal dose has already been established at Week 2 (or at Week 4 ), no further 
dose escalation will be allowed during the dose optimization period and the subject will continue at that dose until the end of the 12 -week treatment period.   However, subjects who had 
a dose escalation may have a dose reduction at any time.  
10.2. Study Drug Storage  
NBI-98854 and placebo capsules must be stored at controlled room temperature (CRT) (20˚C to 
25˚C or 68˚F to 77˚F) under the conditions specified in the Investigator’s Brochure and in a locked area accessible only to the pharmacist (or designee) until dispensing.  Excursions outside this range will be allowed provided they meet the following conditions:  
• Storage between refrigerated conditions (2˚C or 36˚F) and CRT (25˚C or 77˚F) for an unspecified length of time.  
• Storage at temperatures above 25˚C (77˚F) but no more than 30˚C (86˚F) for up to 
3 months. 
• Storage at temperatures above 30˚C (86˚F) but no more than 40˚C (104˚F) for up to 24 hours. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 44
 
10.3. Study Drug Packaging and Labeling 
All packaging and labeling operations will be performed per Good Manufacturing Practice and 
GCP  rules.  The study drugs will be sent to authorized staff at the study site.  The aut horized 
study staff member must confirm receipt of the study drug to NBI or its designee via the IWRS.  
Study drug will be supplied as capsules in child -resistant blistercard dispensers ; each blistercard 
contains enough study drug for 14 days of dosing plus 3 extra dose days.  The blistercards will 
contain capsules of NBI -98854 20 mg or 40 mg; or matching placebo. 
Each blistercard dispenser will be labeled with a single- panel label and secured with tamper 
evident seals.  Label text will include but is not limited to the protocol number, dosage form, route of administration, study drug kit number, sponsor name and address, storage condition, and the statement “Caution – New Drug:  Limited by Federal (or US) Law to Investigational 
Use.”  
10.4. Blinding  
This study includes a 12-week , double-blind, placebo -controlled treatment period during which 
the subject, investigator, all study site personnel, and the Sponsor will be blind ed to the 
subject’s treatment.  
The randomization code will be broken for an individual subject if the subject is pregnant, experiences an SAE that the investigator feels cannot be adequately treated without knowing the identity of the subject’s treatment assignment , or for regulatory reporting requirements.  All 
attempts to contact the NBI Medical Monitor (refer to Section  11.6.3 for contact information) 
must be made before unblinding a subject.  The unblinding form that contains the date, time, the reason the blind was broken, and name of NBI representative contacted must be completed.  
10.5. Study Drug Administration  
Study drug will be administered qd at bedtime at home under the supervision of the subject’s 
parent/legal guardian and the capsules  must be swallowed with at least 4 ounces of water , with 
or without food, every day for the 12-week treatment period.  If a subject forgets or is unable to take the study drug at bedtime, the subj ect should skip that dose and resume normal dosing the 
following day.  Subjects or their parents/legal guardians  will record the date and time of study 
drug dosing each day on the labels provided on the study drug packaging form. 
10.6. Drug Compliance and Accountability  
Subjects will bring all unused study drug  and empty study drug packaging material to the center 
at each study visit for drug accountability and reconciliation by study center personnel.  A compliance check will be performed by counting the capsules returned at each study visit . 
The quantity of study drug dispensed, used, and returned will be recorded on a dispensing log or otherwise documented.  The quantity of study drug lost or destroyed must also be accounted for and documented.  The designated pharmacist or qualified personnel will be responsible for maintaining accurate records of the quantity and dates of all study drug supplies received, dispensed, and returned. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 45
 
10.7. Study Drug Return 
Written documentation to account for study drug and study drug materials is mandatory; all 
unused study drug and study drug materials must be kept in a secure location for final accountability and  reconciliation.  Returned study drug and study drug material must be 
accounted for on a study drug return form provided by NBI or designee.  The investigator must provide a written explanation for any destroyed or missing study drug or study drug materials.  
Returns will be shipped to NBI or its designee at the completion of the study according to instructions provided by NBI or its designee.  Study drug return forms must be completed for the shipment of returns and sent with the study drug and study drug m aterials.  One copy of the 
study drug return form will be retained in the investigator’s study file.  
All returned study drug and study drug materials should be stored, inventoried, reconciled, and returned according to applicable state and federal regulations and study procedures. 
11. ADVERSE EVENTS  
All AEs, whether observed by the investigator, reported by the subject, noted from laboratory findings, or identified by other means, will be recorded from the time the subject signed the ICF until the subject’s final study visit (Week 14 or upon early termination ). 
11.1. Definition  
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.  During the study, clinically significant adverse changes in clinical status, ECGs, laboratory values (not associated with an AE or concurrent medical 
condition), or physical examinations are considered AEs.  Any subject complaint associated with such an abnormal finding will also be reported as an AE.  
AEs include, but are not limited to:  (1) a worsening or change in nature, severity, or frequency 
of conditions present at the start of the study; (2) subject deterioration due to primary illness; (3) intercurrent illness; and (4) drug interaction.  
If at any time after the baseline visit (Day 1), the subject’s response to the suicidal ideation section of the C -SSRS is worse than the baseline assessment; it will be documented as an AE.  
All suicidal behaviors will be documented as an AE.  
Subjects should be questioned in a general way, without asking about the occurrence of any specific symptom.  The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information.  In such cases, the diagnosis should be docume nted as the AE and not the individual signs/symptoms.  Following questioning and 
evaluation, all AEs, whether believed by the investigator to be related or unrelated to the study drug, must be documented in the subject’s medical records, in accordance with  the 
investigator’s normal clinical practice and on the AE eCRF.  Each AE is to be evaluated for duration, intensity, frequency, seriousness, outcome, other actions taken, and relationship to the study drug.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 46
 
The following are not considered AEs:  
• Continuous persistent disease/symptom present before drug administration, unless it 
unexpectedly progresses, or increases in severity following drug administration . 
• Recurrence of TS symptoms, unless worsened from baseline. 
• Pregnancy. 
11.2. Intensity of Adverse Events  
AEs must be graded for intensity.  An intensity category of mild, moderate, or severe, as 
defined in Table 4, must be entered on the AE eCRF.  It should be noted that the term “severe” 
used to grade intensity is not synonymous with the term “serious.”  
Table 4: Intensity of Adverse Events 
Grade  Intensity  
Mild  An AE that is usually transient and may require only minimal treatment or 
therapeutic intervention.  The event does not generally interfere with usual activities 
of daily living.  
Moderate  An AE that is usually alleviated with additional specific therapeutic intervention.  
The event interferes with usual act ivities of daily living, causing discomfort but 
poses no significant or permanent risk of harm to the research participant.  
Severe  An AE that interrupts usual activities of daily living, or significantly affects clinical 
status, or may require intensive therapeutic intervention.  
11.3. Relationship to Study Drug  
The investigator will document his/her opinion of the relationship of the AE to treatment with study drug using the criteria outlined in  Table 5.   An AE is deemed associated with the use of 
the study drug “if there is a reasonable possibility that the drug caused the AE” (otherwise referred to as a suspected adverse reaction).  Reasonable possibility means there is evidence to suggest a causal relationship between the drug and the AE (Title 21 CFR 312.32 [a]). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 47
 
Table 5: Relationship of Adverse Events to Study Drug  
Relationship  Description  
Definite  A reaction that follows a reasonable temporal sequence from administration of the drug or in 
which the drug level has been established in body fluids or tissue; that follows a known or 
expected response pattern to the suspected drug; and that is confirmed by improvement o n 
stopping or reducing the dosage of the drug, and reappearance of the reaction on repeated 
exposure.  
Possible  An adverse event in which there is reasonable possibility that the drug caused the event.  
Reasonable possibility means there is evidence to suggest a causal relationship between the 
drug and the adverse event.  
Unlikely  A reaction that follows a reasonable temporal sequence from administration of the drug; that 
follows a known or suspected response pattern to the suspected drug; but that could 
reasonably be explained by known characteristics of the subject’s clinical state.  
Not Related  Any event that does not meet the above criteria.  
11.4. Recor ding Adverse Events  
For randomized subjects, each AE will be listed as a separate entry on an AE eCRF.  Screen 
failure subjects will have AE information noted in the source documentation.  The investigator (or designee) will provide information on dates and times of onset and resolution, intensity, seriousness, frequency, action(s) taken, changes in study drug usage, relationship to study drug, and outcome. 
The following categories of medical events that could occur during participation in a clinical 
study must be reported within 24 hours to NBI or its designee: 
• SAE , including death (Refer to Section  11.6). 
• Pregnancy (refer to Section  11.7). 
• Events of suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with 
some intent to act, without specific plan) or type 5 (active suicidal ideation with specific 
plan a nd intent) based on the C -SSRS.  
11.5. Post-Study Follow -Up of Adverse Events  
All AEs, including clinically significant changes in ECGs, physical examination findings, or isolated clinically significant laboratory findings must be followed until the event resolves, the condition stabilizes, the event is otherwise explained, or the subject is lost to follow -up.  If 
resolved, a resolution date should be documented on the eCRF.   
AEs ongoing at the final visit or upon early termination will be followed for as long as 
necessary to adequately evaluate the subject’s safety or until the event stabilizes or resolves or 
until the subject is lost to follow -up.  The investigator is responsible for ensuring that follow-up 
includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE.  This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals, as is practical.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 48
 
11.6. Serious Adverse Events  
All SAE s will be recorded from the time the subject has signed the ICF until 30 days after the 
last dose of study drug. 
11.6.1. Definition of a Serious Adverse Event  
An SAE is any AE that results in any of the following outcomes:  
• Death.  
• A life-threatening  AE.  Life threa tening means that the subject was, in the view of the 
investigator or sponsor, at immediate risk of death from the reaction as it occurred.  It does 
not mean that hypothetically the event might have caused death if it occurred in a more serious form. 
• Inpat ient hospitalization or prolongation of existing hospitalization.  Hospitalization for 
elective treatment or a preexisting  condition that did not worsen during the clinical 
investigation is not considered an AE.  Hospitalization or nursing home admission f or the 
purpose of caregiver respite is not considered an AE.  Complications that occur during hospitalization are AEs, and if a complication prolongs hospitalization, the event is considered serious.  Treatment in a hospital emergency room is not a hospitalization.  
• A persistent or significant incapacity or substantial disruption of a person’s ability to 
conduct normal life functions. 
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life threatening, or require 
hospitalization.  These events may be considered serious when, based on appropriate medical judgment, they may jeopardize the health of the subject and may require medical or surgical intervention to prevent one of the outcomes listed.  Any other event thought by the investigator to be serious should also be reported, following the reporting requirements detailed in this section.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
11.6.2. Managing Serious Adverse Events  
Subjects experiencing an SAE or an emergency situation will be examined by a physician as 
soon as possible.  The physician in attendance will do whatever is medically needed for the safety and well -being of the subject.  The subject will remain under observation as long as 
medically indicated.  Appropriate laboratory studies will be conducted until all  parameters 
return to normal or are otherwise explained or stable.  The subject will be followed until the SAE resolves or until the subject is medically stabilized.  The investigator (or designee) will notify the NBI Medical Monitor (and the IRB, if neces sary) immediately (within 24 hours) of 
the SAE and the outcome of the SAE.  
If within the time of informed consent until 30 days after the last dose of study drug, an investigator becomes aware of an SAE, then the event must be documented and reported as described in Section  11.6.3.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 49
 
11.6.3. Reporting Serious Adverse Events and Other Immediately Reportable Events  
Serious AEs and other immediately reportable even ts (defined in Section  11.4) must be reported 
within 24 hours of first knowledge of the event by study personnel to the NBI Medical Monitor 
or NBI Clinical Drug Safety (CDS) Department.  Reports of SAEs or pregnancies should be followed by a fax or email of the SAE or Pregnancy Form .  It is important that the investigator 
provide his or her assessment of relationship to study drug at the time of the initial SAE report.  
For SAEs or Other Immediately Reportable Events, contact CDS:  
 CDS telephone:  
 CDS  facsimile:  
 CDS e -mail:   
 NBI Medical Monitor:   Telephone:  
         Cell phone:  
11.6.4. Expedited Safety Reports 
Neurocrine Biosciences, Inc. or its representatives will submit an Expedited Safety Report for any suspected adverse reaction (as defined in Section  11.3) that is considered both serious and 
unexpected within 15 calendar days and for a ny unexpected fatal or life- threatening experience 
within 7 calendar days via telephone or facsimile; or according to country -specific regulations.  
Neurocrine Biosciences, Inc. or its representatives will send copies of each safety report 
submitted to regu latory authorities to the investigators.  The safety report must be submitted to 
the appropriate IRB as soon as possible.  Documentation of the submission to the IRB and receipt by the IRB (if applicable) must be retained for each safety report.  
11.7. Pregnancy  
Pregnancy is neither an AE nor an SAE unless the criteria for an SAE are met.  However, all pregnancies in female subjects who received NBI -98854 will be followed to assess for 
congenital anomaly.  Subjects must be counseled at all visits to continue using  contraception 
(see inclusion criterion #10 in Section  8.1) until 30 days (females) or 90 days (males)  after the 
last dose of study drug .  If at any time between the time the subject signs the ICF and the last 
study visit a subject believes she is pregnant, the subject will be instructed to stop taking the study medication and return to the study center within 24 hours and undergo a serum pregnancy test to confirm pregnancy.  
All confirmed pregnancies, in subjects who received study drug, must be immed iately reported 
to NBI (refer to Section  11.6.3 for contact information), followed by fax or email of the 
pregnancy form to NBI CDS.  A first trimester ultrasound will be required for all confirmed pregnancies.  Pregnancies in subjects who received NBI -98854 will be followed until resolution 
(ie, termination [voluntary or spontaneous] or birth). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 50
 
12. DOCUMENTATION OF DAT A 
12.1. Case Report Form  
The case report fo rm data for this study are being collected with an electronic data capture 
(EDC) system (Rave®) provided by Medidata Solutions Incorporated, NY, USA.  The EDC 
system and the study -specific eCRFs will comply with Title 21 CFR Part 11.  The 
documentation related to the validation of the EDC system is available through the vendor, 
Medidata, while the validation of the study specific eCRFs will be conducted by NBI and the required documentation will be maintained in the Trial Master File.  
The investigator will document subject data in his/her own subject files.  These subject files will serve as source data for the study.  All eCRF data required by this protocol will be recorded by authorized study personnel in the EDC system, with the exception of data captured  in an 
electronic format, which will be loaded electronically into the appropriate eCRFs.  All data entered into the eCRF will be supported by source documentation.  The eCRF for each subject must be reviewed by the investigator and signed on the appropriate eCRF page(s).  This should be done as soon as possible after the subject completes the study.   
The investigator or an authorized member of the investigator's staff will make any necessary additions/corrections to the eCRF.  All change information, incl uding the date, person 
performing the corrections, and reason for the change will be available via the electronic audit trail, which is part of the EDC system.  The eCRFs will be reviewed periodically for completeness, legibility, and acceptability by NBI (or designee).  NBI will also be allowed 
access to all source documents and medical records pertinent to the study in order to verify eCRF entries.  The Principal Investigator will review the eCRFs for completeness and accuracy and enter his or her electronic signature on the eCRFs as evidence thereof.  
Medidata will provide access to the NBI portal of the EDC system for the duration of the study 
through a password- protected method of internet access.  Such access will be removed from 
investigator sites at the end of the site's participation in the study.  Data from the EDC system will be archived on appropriate data media (CD ROM, etc.) and provided to the investigator at that time as a durable record of the site's eCRF data.  Although not required, the inve stigator 
may make paper printouts from that media.  
All clinical work conducted under this protocol is subject to GCP regulations.  This includes an inspection by NBI and/or health authority representatives at any time.  The Principal Investigator will agree to the inspection of study -related records by health authority 
representatives and/or NBI. 
12.2. Data Capture, Review, and Validation  
Data entered in the EDC system will be verified against the source data by NBI (or designee).  Any discrepancies will be corrected on -line by authorized site personnel.  After completion of 
the entry process, automated (computer -generated) logic checks will run in order to identify 
items such as inconsistent study dates.  In addition, manual review/checks may be performed by NBI on the data.  Any inconsistencies/errors/omissions identified will be sent to the site (via an 
electronic query) for the necessary corrections to be made to the eCRF.  Once entered and saved in an eCRF, data immediately become part of the study database and are available to NBI.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 51
 
12.3. Coding Dictionaries  
AEs and medical history will be coded using the chosen version of the Medical Dictionary for 
Regulatory Activities (MedDRA).  Prior and concomitant medications will be coded using the 
chosen version of the World Health Organization Drug Dictionary (WHO Drug).  
13. STATISTICAL AND ANALYTICAL PLAN  
Descriptive and inferential statistical methods will be used to evaluate and summarize the data from this study.  The term “descriptive statistics” refers to the number of subj ects (n), mean, 
median, SD, SEM, minimum, and maximum for continuous and ordinal categorical variables; and refers to the number and percentage of subjects for categorical variables.  The term “inferential statistics” refers to hypothesis tests which will be performed to assess differences 
between the NBI -98854 treatment group and the placebo treatment group for selected efficacy 
variables based on the pooled weight groups (<50 kg and ≥50 kg).  Note that descriptive statistics will be presented for the pool ed weight groups and for each weight group separately, 
unless specified otherwise.  Only pooled weight groups will be used for inferential statistics.  
The primary efficacy endpoint is the change from baseline (Day 1) to the end of Week 12 in the YGTSS TTS  as generated by the certified site rater using the Rater  Station software.  The 
secondary efficacy endpoints are:  change from baseline to the end of Week 12 in CGI-Tics-Severity score, TTS responder status at Week 12 (a responder is defined as having a 
≥30% reduction in TTS from baseline), and CGI- TS-Improvement responder status at Week 12 
(a responder is defined as having a CGI- TS-Improvement score of either a 1 [“very much 
improved”] or a 2 [“much improved”]).  Exploratory efficacy endpoints include the PUTS total 
score change from baseline to the end of Week 12, the CGI- TS-Improvement score at the end of 
Week 12, the C&A-GTS -QOL total score change from baseline to the end of Week 12, as well 
as changes from baseline to the end of Week 12 for the Global Tic Severity and Impairment scores from the YGTSS.  Efficacy data will also be summarized from other timepoints (eg, Weeks 2 through 10). 
The primary method of analysis of the YGTSS TTS change from baseline will be a mixed -
effect model repeated measures (M MRM) analysis including the scores at Weeks 2, 4, 6, 8, 10, 
and 12 based on the full  analysis set  (FAS) .  Supplemental sensitivity analyses of the primary 
efficacy endpoint will also be conducted.  
Nominal (raw) two -sided p values will be reported for all h ypothesis tests, although a procedure 
to control for multiple comparisons  will be applied when interpreting the statistical significance 
of the results of the analyses of the primary efficacy endpoint and the secondary efficacy 
endpoints.  
The analysis plan provided in this protocol represents a brief description of the planned 
analyses.  A comprehensive and detailed statistical analysis plan (SAP) will be generated prior to study database lock and treatment unblinding.  The SAP may include additional analy ses and 
data summaries not described in this protocol and will include detailed descriptions of graphical data displays that will support the tabular summaries.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 52
 
13.1. Analysis Sets  
Three analysis sets will be defined for this study.  The safety analysis set will  include all 
subjects who are randomized to a treatment group, take at least one dose of study drug, and 
have any postbaseline safety data.  The FAS will include all subjects who are randomized to a 
treatment group and who have at least one evaluable TTS  change from baseline during the 
12-week , double- blind treatment period.  The per -protocol (PP) analysis set will include all 
subjects in the FAS who have a detectable plasma concentration of NBI -98854 at Week 12 
(unless randomized to placebo) and no efficacy- related important protocol deviations.  
Additional analysis set criteria may be specified in the SAP.  
13.2. Sample Size  
The protocol-specified sample size of 60 subjects per treatment group is based on a power calculation for the YGTSS TTS change from baseline using a two -sample t -test with a two -
sided Type I error of 0.05.  Power calculations based on this sample size under 3 dropout rate scenarios for 2 hypothesized effect sizes are summarized in the table below.  Note that the effect size is defined as the mean difference between the NBI -98854 treatment group and the placebo 
group divided by the common SD (eg, a mean difference of 8 divided by an SD of 10 yields an 
effect size of 0.8).  
 
Dropout Rate  Number of Subjects  per 
Treatment Group  Effect Size  Power  
0% 60 0.75 98% 
0.85 99% 
10% 54 0.75 97% 
0.85 99% 
15% 51 0.75 96% 
0.85 98% 
 Standard deviations reported in the literature for TS studies evaluating changes in the YGTSS 
TTS (with or without placebo controls) have generally been in the range of 7.5 to 9.5, and in placebo -controlled studies, mean differences between active and placebo arms have been in the 
range of 5 to 9 (Jankovic et al., 2010 ; Yoo et al., 2013 ; ClinicalTrials.gov [STUDY_ID_REMOVED]).  The 
effect sizes of 0.75 and 0.85 mentioned above are representative of effect sizes seen in these published reports.  
13.3. Handling of Missing Data  
Conventions for the handling of missing data will be described in the SAP. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 53
 
13.4. Enrollment and Disposition of Subjects  
The summary of subject enrollment and disposition  will display the number of subjects who 
were randomized to each treatment group, who completed the dose optimization period (ie, up 
to Week 6), who competed the dose maintenance period (ie, up to Week 12), and who completed the study.  The number of subje cts who did not complete the study will also be 
summarized, both overall and according to the reason for early discontinuation. 
A separate summary of randomization by study site will be presented.  This summary will 
display the number of subjects randomize d to each treatment group by site.  
13.5. Demographics and Baseline Characteristics  
Demographic data (age, gender, race, and ethnicity) and baseline characteristics (including height, weight, body mass index [ BMI], CYP2D6 genotype status, age at TS diagnosis, and  
baseline values for the YGTSS TTS) will be summarized with descriptive statistics.  Medical history will be summarized according to MedDRA System Organ Class (SOC) and Preferred Term (PT).  
13.6. Study Drug Dosing and Compliance  
The number and percentage of subj ects who are dose compliant (at least 80% of expected 
number of doses taken) will be summarized with descriptive statistics by visit (Weeks 2, 4, 6, 8, 10, and 12).   
The number and percentage of subjects with dose adjustments will be summarized by visit.  
13.7. Pharmacokinetic Data  
The plasma concentrations of NBI -98854 and the metabolite NBI-98782 will be summarized 
with descriptive statistics by visit (Day 1 and Weeks  2, 4, 6, 8, 10, 12, and 14) and dose (last 
dose received prior to blood sample being drawn).  Concentrations below the lower limit of 
quantification will be set equal to zero for all plasma concentration summaries.  These data will be summarized for each weight group separately.  
13.8. Efficacy Data  
The efficacy measures in this study include the YGTSS, PUTS, CGI -Tics-Severity, 
CGI-TS-Improvement, and C&A-GTS -QOL.  Several derived variables based on these 
measures (eg, the YGTSS TTS) will be summarized with descriptive statistics, and inferential statistics will be calculated for selected variables as des cribed in the following paragraphs.  The 
SAP will provide a full description of the derived variables that will be summarized for these efficacy measures.  
13.8.1. Primary Efficacy Endpoint  
The primary efficacy endpoint for this study is the change from baseline (D ay 1) to the end of 
Week  12 in the YGTSS TTS (Total Tic Score) as generated by the certified site rater using the 
Rater  Station .  Changes from baseline to Weeks 2 through 10 are exploratory efficacy 
endpoints. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 54
 
Descriptive statistics will be presented by treatment group for the TTS observed values (ie, the 
raw data) and changes from baseline at each visit through Week 14.  Descriptive statistics will be presented for both the FAS and the PP analysis set.    
The primary analysis of the TTS will be a n MMRM ana lysis, which includes the changes from 
baseline to Weeks 2, 4, 6, 8, 10, and 12, and is based on the FAS .  The model will include the 
baseline TTS as a covariate, and weight group, treatment group, visit, treatment group by visit interaction, and baseline covariate by visit interaction as fixed effects.  Subject will be included 
as a random effect.  Study site will not be included in the model, as there are many  sites 
(approximately 55), with most sites anticipated to enroll a small number of subjects.  
Treatment group comparisons of the NBI-98854 treatment group vs. placebo at each visit will be performed by constructing linear contrasts (or equivalent programming code) for differences between treatment group least -squares (LS) means.  Nominal (raw) two -sided p values for 
testing the significance of these differences and associated 95% confidence intervals will be reported in summary tables.  
A supportive analysis using the MMRM model will be performed with the PP analysis set.  
The MMRM analysis will be i mplemented with the PROC MIXED procedure of SAS
®, using 
the restricted maximum likelihood method, an unstructured within -subject covariance matrix, 
and denominator degrees of freedom from the Kenward-Roger method.  If  convergence is not 
obtained with the unstructured covariance matrix, a Toeplitz covariance structure will be used.  
Additional supportive analyses of the TTS change from baseline to the end of Week 12 will be 
performed using analysis of covariance (ANCOVA) models.  The ANCOVA models will 
include the baseline TTS as a covariate and weight group and treatment group as fixed effects.  Response (outcome) variables for the ANCOVAs include the Week 12 TTS score (ie, a complete cases analysis) and the last on -treatment TTS score (ie, a last -observation-carried 
forward [LOCF] analysis).  These analyses  will be performed using the FAS. 
Additional analyses, including sensitivity analyses to assess the missing at random assumption of the MMRM, will be described in the SAP.  
13.8.2. Secondary Efficacy Endpoints 
CGI-Tics -Severity  
A secondary efficacy endpoint for this study is the change from baseline to the end of Week 12 
in CGI- Tics-Severity score.  Changes from baseline to Weeks 2 through 10 are exploratory 
efficacy endpoints. 
Descriptive statistics will be presented by treatment group for the CGI- Tics-Severity observed 
values (ie, the raw data) and changes from baseline at each visit through Week 14.  Frequency 
counts using the response categories will also be presented by visit.  Descriptive statistics will be presented for both the FAS and the PP analysis set.    
The primary analysis of CGI- Tics-Severity will be an MMRM analysis which includes the 
changes from baseline to Weeks 2, 4, 6, 8, 10, and 12 and is based on the FAS.  The MMRM model will be similar to the model described above for the TTS analysis, with the exception that the covariate in the model will be the baseline value of the CGI -Tics-Severity score.  As 
indicated above for the TTS MMRM analysis, nominal two -sided p values for testing the 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 55
 
significance of treatment group differences and associated 95% confidence intervals will be 
reported in summary tables; however, interpretation of the p value for the treatment group comparison at Week 12 will be based on a procedure which controls for multiple co mparisons 
(Section  13.8.3). 
A supportive analysis of the CGI- Tics-Severity scores will be performed using the MMRM 
analysis based on the PP analysis set.  Additional supportive analyses of the CGI -Tics-Severity 
scores will be described in the SAP.  
Responder Endpoints  
The following response statuses at Week 12 will serve as additional secondary endpoints:  
• TTS responder:  a subject whose TTS value is reduced by at least 30% from baseline. 
• CGI-TS-Improvement responder:  a subject whose CGI -TS-Improvement score is either a 
1 (“very much improved”) or a 2 (“much improved”). 
Response at Weeks 2 through 10 are exploratory efficacy endpoints. 
The TTS responder criteri on was selected based on a review of studies examining the threshold 
of tic reduction associated with meaningful clinical response (Storch et al. , 2011; Jeon et al. , 
2013). Descriptive statistics for each responder definition will be presented by treatment group for the 
number and percentage of subjects classified as responders at each postbaseline visit.  
Analyses comparing the NBI -98854 treatment group to placebo will be pe rformed using the 
Cochran- Mantel -Haenszel (CMH) procedure, with baseline weight group as a stratification 
variable.  
13.8.3. Procedure to Control for Multiple Comparisons  
A fixed- sequence testing procedure will be followed for the primary and secondary efficacy 
endpoints analyses to  control for multiple comparisons (ie, comparing treatment groups for each 
of the endpoints).  The fixed-sequence testing procedure will consist of performing the 
hypothesis tests in the following prespecified order:  
1. Primary endpoint:  YGTSS TTS change from baseline to Week 12 (NBI -98854 vs. 
placebo treatment groups using the FAS). 
2. Secondary endpoint:  CGI -Tics-Severity change from baseline to Week 12 (NBI -98854 
vs. placebo treatment groups using the FAS) . 
3. Secondary endpoint:  TTS response at Week 12 (NBI-98854 vs. placebo treatment groups using the FAS). 
4. Secondary endpoint:  CGI- TS-Improvement response at Week 12 (NBI-98854 vs. placebo 
treatment groups using the FAS). 
Each step in the sequential testing procedure uses a local two-sided 0.05 level of significance 
for the null hypothesis being tested.  The null hypothesis  at each step of the procedure can  only 
be rejected if all null hypotheses in prior steps were rejected.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 56
 
13.8.4. Exploratory Efficacy Endpoints 
Efficacy endpoints not described in the preceding paragraphs are considered exploratory 
endpoints.  Exploratory efficacy endpoints will include the PUTS total score change from baseline to the end of Week 12, CGI -TS-Improvement score at the end of Week 12 , 
C&A-GTS -QOL total score change from baseline to the end of Week 12, as well as mean 
changes from baseline to the end of Week 12 for the Global Tic Severity and Impairment scores from the YGTSS .  Efficacy data will also be summarized from other timepoints (eg, Weeks 2 
through 10).  Details regarding the analyses of these endpoints will be provided in the SAP.  
13.9. Safety Data  
Treatment -emergent adverse events (TEAEs ), categorized by MedDRA SOC and/or PT will be 
summarized in frequency tables.  The TEAE summary tables will include the number  and 
percentage of unique s ubjects experiencing each event . 
Summary tables will be presented including all TEAEs and TEAEs according to maximum intensity.   
Additional summaries will be presented for TEAEs leading to study drug dose reducti ons, 
premature discontinuations from the study, SAEs, and fatal TEAEs . 
Clinical laboratory, vital signs, ECG, C -SSRS, ESRS -A, CY -BOCS, CDRS-R, and ADHD 
Rating Scale-5 data will be summarized with descriptive statistics.  Potentially clinically significant (PCS) values for selected clinical laboratory and vital signs variables will be summarized.  Prior and concomitant medications will be summarized according to WHO Drug Anatomical Therapeutic Chemical Classification (ATC) categories.  
Any additional planned safety analyses will be described  in the SAP.  
13.10.  Software 
Statistical calculations and summaries will be generated using SAS software version 9. 4 or 
later.  
13.11.  Interim Analysis  
An interim analysis is not planned for this study.  
14. REGULATORY AND ETHIC AL ISSUES  
14.1. General Legal References  
The study will be carried out according to the provision of the US CFR, the US FDA, Health 
Canada, and the ICH Guidelines for GCP.  All clinical work conducted under this protocol is 
subject to GCP rules.  This includes an inspection by  NBI or its representative, health authority , 
or IRB representatives at any time.  The investigator must agree to the inspection of study -
related records by health authority representatives and/or NBI or its designee.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 57
 
14.2. Institutional Review Board  
The final approved protocol, the ICF , and assent document will be reviewed by the IRB for the 
clinical site.  The committee’s decision concerning conduct of the study will be sent in writing 
to the investigator and a copy will be forwarded to NBI.  The investigator must agree to make any required progress reports to the IRB, as well as reports of SAEs, life-threatening problems, 
or death.  
14.3. Protocol Adherence and Amendments  
The protocol must be read thoroughly, and the instructions must be followed exactly .  Any 
changes in the protocol will require a formal amendment.  Such amendments will be agreed upon and approved in writing by the investigator and NBI.  The IRB will be notified of all amendments to the protocol.  Amendments to the protocol will not be impl emented until written 
IRB approval has been received.  
14.4. Required Documents  
The investigator must provide to NBI or its representatives the following documents before the enrollment of any subject (originals  should be kept by the investigator in the investig ator’s 
regulatory document binder): 
• Signed copy of the approved protocol. 
• Investigator’s Brochure acknowledgement page.  
• Completed and signed statement of investigator (Form FDA 1572  and/or Clinical Trial Site 
Information Form – as applicable). 
• Curriculum vitae and current medical license of the investigator and subinvestigators.  
• Financial disclosure information as required.  
• Letter of approval from the IRB for the protocol, consent form, and assent form. 
• Copy of the IRB approved written ICF and a ssent to be used. 
• Laboratory documents (certifications/accreditations, normal ranges) if not provided by a 
central laboratory.  
14.5. Informed Consent  
All parents or legal guardians will provide informed consent with signed and witnessed pediatric assent before t he performance of any study-related procedures.  
Each subject’s chart will include the signed ICF with signed and witnessed pediatric assent for 
study participation.  When the study treatment is completed and the eCRF has been monitored, the ICF and signed and witnessed pediatric assent will be kept in the investigator’s central study 
file.  Regulatory authorities may check the existence of the signed ICF and the signed and 
witnessed pediatric assent in this central study folder.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 58
 
14.6. Study Monitoring 
Throughout the course of the study, the study monitor will m ake frequent contacts with the 
investigator.  This will include emails, telephone calls,  and on- site visits .  During the on- site 
visits, the eCRFs will be reviewed for completeness and adherence to the proto col.  As part of 
the data audit, source documents will be made available for review by the study monitor.  The 
study monitor will also perform drug accountability checks and may periodically request review of the investigator study file to ensure completeness of documentation in all respects of clinical study conduct. 
Upon completion of the study, the study monitor will arrange for a final review of the study 
files after which the files should be secured for the appropriate time period.  The investigator or appointed delegate will receive the study monitor during these on-site visits, will cooperate in 
providing the documents for inspection, and respond to inquiries.  In addition, the investigator will permit inspection of the study files by authorized representatives of the regulatory agencies.  
14.7. Quality Assurance  
The study will be conducted in accordance with NBI’s standard operating procedures designed to ensure that all procedures are in compliance with GCP and FDA Guidelines, Health Canada Guidelines, and according to national law.  Quality assurance audits may be performed at the discretion of NBI.  
14.8. Record Retention  
Federal regulations require that records of drug disposition, eCRFs, and all reports of this investigation shall be retained by the investigato r for a minimum of 2 years after notification by 
NBI that the regulatory authorities have been notified of the study's termination, or 2 years after approval of the marketing application.  If the investigator is unable to retain the study documents for the required amount of time, NBI must be informed of the individual who will be assuming this responsibility.  
14.9. Confidentiality  
NBI and the clinical site affirm and uphold the principle of the subject’s right to protection against invasion of privacy.  Throughout this study, all data will be identified only by an identification number and, where applicable, subject’s initials and birth date.  
All information concerning this study , and which was not previously published is considered 
confidential information.  Thi s confidential information shall remain the sole property of NBI; it 
shall not be disclosed to others without written consent of NBI; and shall not be used except in the performance of this study. 
The information compiled during the conduct of this clinical study is also considered 
confidential and may be disclosed and/or used only by NBI as deemed necessary.  To allow the use of the information derived from this clinical study and to ensure compliance with current federal regulations, the investigat or is obliged to furnish NBI with the complete test results and 
all data compiled in this study.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 59
 
15. STUDY COMMENCEMENT A ND DISCONTINUATION  
Upon satisfactory receipt of all required regulatory documents, NBI (or designee) will arrange 
that all study material be delivered to the study site.  Subject entry should not begin until after the required regulatory documents are confirmed as received and the Investigator Meeting/Initiation Meeting has occurred.  All personnel expected to be involved in the conduct of the study will undergo orientation to include review of study protocol, instructions for eCRF completion, AE reporting, and overall responsibilities including those for drug accountability and study file maintenance.  
If the study is discontinued, all subject s should undergo a complete follow-up examination.  
Any clinically relevant finding, including laboratory values of potential clinical concern, and adverse experiences will be followed until they resolve or return to a clinically acceptable level.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 60
 
16. REFERENC ES 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition. 1994. 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition. 2013. Baxter LR , Guze  BH. Neuroimaging.  In: Kurlan, R. (Ed), Handbook of Tourette syndrome and 
related tic and behavioral disorders.  Rochester: Marcel Decker Inc. ; 1993. 
Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J, et al. The functional 
neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology. 1993 Dec;9(4):277-91. 
Cavanna AE, Nani A. Tourette syndrome and consciousness of action. Tremor Other 
Hyperkinet Mov (NY). 2013 Sep 23;3. 
Cavanna AE, Luoni C, Selvini C, Blangiardo R, Eddy CM, Silvestri PR, et al. The Gilles de la Tourette Syndrome- Quality of Life Scale for children and adolescents (C&A -GTS -QOL): 
development and validation of the Italian ver sion. Behav Neurol. 2013;27(1):95-103. 
Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the liter ature. Clin Ther. 2012 Jul;34(7):1487-504. 
Chouinard S, Ford B. Adult onset tic disorders. J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):738-43. 
Chouinard G, Margolese HC.  Manual for the Extrapyramidal Symptom Rating Scale (ESRS).  Schizophr Res. 2005 Jul 15;76(2-3):247-65. 
Study Registry ID: [REMOVED]. Otsuka Pharmaceutical Development & 
Commercialization, Inc. Study evaluating the safety and efficacy of fixed -dose once-daily 
aripiprazole in children and adolescents with Tourette’s Disorder https://www.clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=[STUDY_ID_REMOVED]&rank=1 [Accessed 28 June 2017]. 
Felling RJ , Singer HS. Neurobiology of tourette syndrome: current status and need for further 
investigation. J Neurosci. 2011 Aug 31;31(35):12387-95. 
Jankovic J, Jimenez -Shahed J, Brown LW. A randomised, double-blind, placebo-controlled 
study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 
Jan;81(1):70-3. 
Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011 May;26(6):1149-56. 
Jeon S, Walkup JT, Woods DW, Peterson A, Piacentini J , Wilhelm S, et al. Detecting a 
clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials. 2013 Nov;36(2):414-20. 
Kurlan R. Clinical practice. Tourette's Syndrome. N Engl J Med. 2010 Dec 9;363(24):2332-8. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 61
 
Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global 
Tic Severity Scale: initial testing of a clinician -rated scale of tic severity. J Am Acad Child 
Adolesc Psychiatry. 1989 Jul;28(4):566-73. 
Leckman  JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in 
Tourette syndrome: the first two decades. Pediatrics. 1998 Jul;102(1 Pt 1):14-9. 
Pourfar M, Feigin A, Tang CC, Carbon-Correll M, Bussa M, Budman C, et al.  Abnormal 
metabo lic brain networks in Tourette syndrome. Neurology. 2011 Mar 15;76(11):944-52. 
Robertson MM. Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med (Lond). 2011 Feb;72(2):100–7. 
Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A. Pharmacological 
treatment of tic disorders and Tourette Syndrome. Neuropharmacology. 2013 May;68:143-9. 
Shprecher D, Kurlan R. The management of tics. Mov Disord. 2009 Jan 15;24(1):15-24. Storch EA, De Nadai  AS, Lewin AB, McGuire JF, Jones AM, Mutch PJ, et al. Defining 
treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic 
Severity Scale. J Child Adolesc Psychopharmacol. 2011 Dec;21(6):621-7. 
Swain JE, Scahill L, Lom broso PJ, King RA, Leckman JF. Tourette syndrome and tic disorders: 
a decade of progress. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):947–68. Woods DW, Piacentini J, Himle MB, Chang S. Premonitory Urge for Tics Scale (PUTS): initial 
psychometric res ults and examination of the premonitory urge phenomenon in youths with Tic 
disorders. J Dev Behav Pediatr. 2005 Dec;26(6):397-403. 
Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013 Aug ;74(8):e772-80. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-TS2003 
Clinical Study Protocol Amendment No. 2 Final Version
31 July 2018
Confidential
Page 62